zonisamide has been researched along with Aura in 213 studies
Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.
zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Participants with focal epilepsy were randomised to receive lamotrigine, levetiracetam or zonisamide." | 9.41 | Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs. ( Appleton, R; Baker, G; Balabanova, S; Brown, R; Burnside, G; Hindley, D; Howell, S; Hughes, DA; Leach, JP; Maguire, M; Marson, AG; Mohanraj, R; Plumpton, CO; Sills, G; Smith, D; Smith, PE; Taylor, C; Tudur-Smith, C; Williamson, PR, 2021) |
| "Based on these results, zonisamide monotherapy is effective in some dogs with idiopathic epilepsy." | 9.16 | Zonisamide monotherapy for idiopathic epilepsy in dogs. ( Ahn, JO; Chae, JS; Chung, JY; Hwang, CY; Kim, TH; Lee, SY; Seo, KW; Youn, HY, 2012) |
| "To evaluate the effectiveness of zonisamide (ZNS) as monotherapy in children with newly diagnosed epilepsy." | 9.15 | Comparative trial of low- and high-dose zonisamide as monotherapy for childhood epilepsy. ( Chung, HJ; Eom, S; Eun, BL; Eun, SH; Kang, HC; Kim, DW; Kim, HD; Kim, JS; Lee, IK; Lee, JS; Lee, YM; Moon, HK; Suh, ES, 2011) |
| "To report on the first multicenter Italian experience with zonisamide as an add-on drug for refractory generalised or partial epilepsy in children, adolescents and young adults." | 9.14 | Zonisamide in children and young adults with refractory epilepsy: an open label, multicenter Italian study. ( Balestri, P; Coppola, G; Curatolo, P; Franzoni, E; Grosso, S; Iannetti, P; Luchetti, A; Mangano, S; Operto, FF; Parisi, P; Pascotto, A; Pelliccia, A; Verrotti, A, 2009) |
| "This study investigated the efficacy and safety of zonisamide (ZNS) adjunctive therapy in children with intractable epilepsy to existing antiepileptic drugs (AEDs)." | 9.14 | Efficacy and tolerability of adjunctive therapy with zonisamide in childhood intractable epilepsy. ( Kang, HC; Kim, HD; Lee, JS; Lee, YJ; Seo, JH, 2010) |
| "Zonisamide treatment was generally well tolerated and was associated with significant reductions in seizure frequency in this pediatric population with a variety of both partial and generalized medically refractory epilepsy syndromes." | 9.14 | Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy. ( Conry, JA; Pellock, JM; Shinnar, S, 2009) |
| "This study was a prospective, randomized, open-label investigation of the long-term effects of zonisamide (ZNS) monotherapy on cognition and mood of patients with epilepsy." | 9.13 | Long-term cognitive and mood effects of zonisamide monotherapy in epilepsy patients. ( Hwang, YH; Kwon, SH; Lee, BI; Lee, HW; Park, SP; Suh, CK, 2008) |
| "Investigation of the efficacy of zonisamide as an add-on therapy in dogs with refractory epilepsy." | 9.12 | Prospective study of zonisamide therapy for refractory idiopathic epilepsy in dogs. ( Rambeck, B; Tipold, A; von Klopmann, T, 2007) |
| "This study was designed to assess the safety of 25- and 50-mg dosage strengths of zonisamide for initial titration in patients with epilepsy." | 9.11 | Safety of 25- and 50-mg capsules in the initiation of zonisamide therapy in patients with epilepsy: an uncontrolled, open-label study. ( Anthony, S; James, SP; Miller, GS; Montouris, G; Uthman, BM, 2004) |
| "This study was designed to measure the effect of the addition of zonisamide on phenytoin pharmacokinetics under steady-state conditions in patients with epilepsy." | 9.11 | Lack of a clinically significant effect of zonisamide on phenytoin steady-state pharmacokinetics in patients with epilepsy. ( Garnett, WR; Levy, RH; Pan, WJ; Ragueneau-Majlessi, I; Rosenfeld, W; Schmerler, M; Shah, J, 2004) |
| "Postmarketing data about the effectiveness of zonisamide in childhood epilepsy was collected from 759 children with various forms of epilepsy (ages 3 months-15 years) to compare the long-term efficacy of zonisamide in the treatment of epilepsy in intellectually normal versus intellectually disabled children." | 9.11 | Clinical efficacy of zonisamide in childhood epilepsy after long-term treatment: a postmarketing, multi-institutional survey. ( Haginoya, K; Iinuma, K, 2004) |
| "This study examined the efficacy and safety of zonisamide as monotherapy in pediatric patients with epilepsy." | 9.11 | Effects of zonisamide monotherapy in children with epilepsy. ( Kumagai, N; Maezawa, M; Seki, T, 2004) |
| "The present study was designed to assess the effect of the addition of zonisamide (ZNS) on lamotrigine (LTG) disposition and the safety of the combination under steady-state conditions in patients with epilepsy." | 9.11 | Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy. ( Brodie, MJ; Levy, RH; Pan, WJ; Ragueneau-Majlessi, I; Shah, J; Smith, DF, 2005) |
| "Zonisamide (ZNS), a second-generation antiepileptic drug, indicated as add-on treatment of focal epilepsy, has been recently approved as monotherapy for the treatment of partial seizures in adults affected by newly diagnosed epilepsy in Europe." | 8.91 | Zonisamide in the management of epilepsy in the elderly. ( Di Gennaro, G; Fattore, C; Femia, EA; Franco, V; Romigi, A; Vitrani, G, 2015) |
| "At this moment, zonisamide represents a robust option in the treatment of a large number of patients with epilepsy, based on its multiple mechanism of action and efficacy in different situations." | 8.89 | [Zonisamide in the epilepsy treatment: a literature review from add-on therapy to monotherapy]. ( Serrano-Castro, PJ; Villanueva, V, 2013) |
| "From the available clinical data, zonisamide is a viable first-line and adjunctive therapeutic for partial-onset epilepsy and should be considered as an adjunctive therapeutic for a wide-range of generalized epilepsies." | 8.87 | Zonisamide in the treatment of epilepsy. ( Holder, JL; Wilfong, AA, 2011) |
| " Zonisamide is an antiepileptic drug with multiple mechanisms of action, corresponding to efficacy in diverse epilepsy syndromes." | 8.86 | Zonisamide in the treatment of epilepsy. ( Schulze-Bonhage, A, 2010) |
| " Zonisamide is the latest addition to the pharmacological management of epilepsy in Europe, following extensive clinical experience in Japan and the USA." | 8.83 | Zonisamide for the treatment of epilepsy. ( Arzimanoglou, A; Rahbani, A, 2006) |
| "Zonisamide is a novel anticonvulsant that is structurally and mechanistically unique, compared with other antiepilepsy drugs." | 8.81 | Zonisamide in pediatric epilepsy: review of the Japanese experience. ( Glauser, TA; Pellock, JM, 2002) |
| "To investigate caregivers' assessments of outcome in dogs with idiopathic epilepsy (IE) administered levetiracetam (LEV), zonisamide (ZNS), or phenobarbital (PB) monotherapy." | 8.31 | Comparison of caregivers' assessments of clinical outcome in dogs with idiopathic epilepsy administered levetiracetam, zonisamide, or phenobarbital monotherapy. ( Gristina, BR; Muñana, KR; Nettifee, JA; Waldron, RJ, 2023) |
| "To assess the therapeutic efficacy and safety of antiseizure medication (ASM) for a minimum of 6 months, including zonisamide (ZNS), in feline idiopathic epilepsy at a referral hospital in Japan." | 8.31 | Evaluation of antiseizure medications including zonisamide in feline idiopathic epilepsy at a referral hospital in Japan. ( Maeda, S; Motegi, T; Yonezawa, T; Yoshida, S, 2023) |
| "Zonisamide (ZNS) is a new generation antiepileptic drug (AED) used in refractory epilepsy." | 8.12 | Effectiveness of zonisamide in childhood refractory epilepsy. ( Aslan, M; Gungor, S, 2022) |
| "A 3-year-old neutered male golden retriever administered zonisamide for the treatment of seizures showed lethargy and had normal anion gap metabolic acidosis with hypokalaemia, hyperchloremia, and alkaline urine." | 8.12 | Distal renal tubular acidosis and lethargy associated with zonisamide treatment in a dog with idiopathic epilepsy. ( Akashi, N; Hata, A; Itoi, T; Kanda, T; Kutara, K; Miyama, TS; Shimizu, Y; Sugimoto, K, 2022) |
| "Animal data suggest teratogenic effects with zonisamide use and risk of pregnancy losses." | 8.02 | Zonisamide safety in pregnancy: Data from the UK and Ireland epilepsy and pregnancy register. ( Bromley, R; Campbell, E; Craig, JJ; Delanty, N; Heath, C; Hunt, SJ; Irwin, B; Kinney, MO; Liggan, B; MacKillop, L; McCluskey, G; Morrison, PJ; Morrow, J; Murphy, S; Parsons, L; Russell, A; Smithson, WH, 2021) |
| "We aim to evaluate the impact of zonisamide (ZNS) compared to topiramate (TPM) on cognition in patients with epilepsy." | 7.96 | Changes in cognition after introduction or withdrawal of zonisamide versus topiramate in epilepsy patients: A retrospective study using Bayes statistics. ( Brömling, S; Helmstaedter, C; Meschede, C; Moskau-Hartmann, S; Rademacher, M; Surges, R; von Wrede, R; Witt, JA, 2020) |
| "The present findings revealed that zonisamide treatment prevented the development of seizures in animals." | 7.88 | A mechanistic approach to explore the neuroprotective potential of zonisamide in seizures. ( Attri, SV; Kumar, B; Medhi, B; Modi, M; Patial, A; Saikia, B, 2018) |
| "To investigate the change in zonisamide (ZNS) serum concentration and its consequences in pregnant women with epilepsy." | 7.88 | Zonisamide serum concentrations during pregnancy. ( Aurlien, D; Becser Andersen, N; Brodtkorb, E; Christensen, J; Haggag, K; Helde, G; Lillestølen, KM; Nakken, KO; Reimers, A; Surlien Navjord, E, 2018) |
| "Zonisamide is licensed for adjunctive therapy for partial-onset seizures with or without secondary generalisation in patients 6 years and older and as monotherapy for the treatment of partial seizures in adult patients with newly diagnosed epilepsy, and shows a favourable pharmacokinetic profile with low interaction potential with other drugs." | 7.83 | Retention, dosing, tolerability and patient reported seizure outcome of Zonisamide as only add-on treatment under real-life conditions in adult patients with partial onset seizures: Results of the observational study ZOOM. ( Baulac, M; Hamer, H; Kockelmann, E; McMurray, R, 2016) |
| "Although it has been reported that some antiepileptic drugs have inducing or inhibiting effects on lamotrigine (LTG) clearance, whether they have the same effects in Asian epilepsy patients as in those in other countries has not been clarified, especially in children." | 7.83 | The effects of co-medications on lamotrigine clearance in Japanese children with epilepsy. ( Abe, S; Azuma, Y; Ishihara, N; Ito, Y; Itomi, K; Kidokoro, H; Kojima, S; Kurahashi, H; Kurahashi, N; Maruyama, K; Natsume, J; Negoro, T; Okumura, A; Suzuki, M; Takeuchi, T; Tsuji, T; Watanabe, K; Yamada, K; Yamamoto, H, 2016) |
| "To assess the effect and tolerability of zonisamide (ZNS) as adjunctive treatment for difficult-to-treat epilepsy in adult Scandinavian patients." | 7.81 | Retention rate of zonisamide in intractable epilepsy. ( Andersen, H; Lindstrøm, P; Nakken, KO, 2015) |
| "This report describes a dog that developed erythema multiforme in temporal association with administration of the sulphonamide-based anticonvulsant drug zonisamide." | 7.81 | Erythema multiforme associated with zonisamide in a dog. ( Ackermann, AL; Frank, LA; May, ER; McEntee, MF, 2015) |
| "To further assess the safety of adjunctive zonisamide in paediatric epilepsy patients." | 7.80 | Safety and tolerability of zonisamide in paediatric patients with epilepsy. ( Auvin, S; Cross, JH; Giorgi, L; Patten, A, 2014) |
| "Zonisamide is a new generation antiepileptic drug (AED) widely used in children with refractory epilepsy, although until recently, it was used to a large extent as off-label or unlicensed medication due to the lack of evidence-based studies." | 7.80 | Zonisamide: pharmacokinetics, efficacy, and adverse events in children with epilepsy. ( Dahlin, M; Ohman, I; Wallander, KM, 2014) |
| " We performed an open-label, observational study to assess the effects of zonisamide on weight in overweight female epilepsy patients." | 7.78 | Low serum leptin level is associated with zonisamide-induced weight loss in overweight female epilepsy patients. ( Kim, DW; Park, KS; Yoo, MW, 2012) |
| "Concerning zonisamide (ZNS) therapy, data on sexual dysfunction are not available either in patients with epilepsy or in patients with brain tumor-related epilepsy." | 7.77 | Reversible erectile dysfunction in a patient with brain tumor-related epilepsy in therapy with zonisamide in add-on. ( Dinapoli, L; Jandolo, B; Maschio, M; Saveriano, F, 2011) |
| "A 9-year old female spayed Rottweiler was diagnosed with cryptogenic epilepsy and started on zonisamide monotherapy (8." | 7.77 | Possible drug-induced hepatopathy in a dog receiving zonisamide monotherapy for treatment of cryptogenic epilepsy. ( Muñana, KR; Olby, NJ; Schwartz, M, 2011) |
| "To evaluate the effectiveness and tolerability of zonisamide in children with epilepsy." | 7.76 | Effectiveness and tolerability of zonisamide in children with epilepsy: a retrospective review. ( Appleton, RE; Kneen, R; Martland, TR; Tan, HJ, 2010) |
| "We present an implementation of a method we previously reported allowing the newer antiepileptic drugs (AEDs) rufinamide (RFN) and zonisamide (ZNS) to be simultaneously determined with lamotrigine (LTG), oxcarbazepine's (OXC) main active metabolite monohydroxycarbamazepine (MHD) and felbamate (FBM) in plasma of patients with epilepsy using high performance liquid chromatography (HPLC) with UV detection." | 7.76 | Simultaneous HPLC-UV analysis of rufinamide, zonisamide, lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in deproteinized plasma of patients with epilepsy. ( Albani, F; Baruzzi, A; Candela, C; Contin, M; Mohamed, S; Riva, R, 2010) |
| " The current report describes a man who was prescribed zonisamide for epilepsy and subsequently developed widespread skin rash, acute kidney injury, high-grade fever, eosinophilia, liver dysfunction, lymphadenopathy and an increase in antihuman herpesvirus-6 immunoglobulin G titer." | 7.76 | Acute kidney injury caused by zonisamide-induced hypersensitivity syndrome. ( Fujita, Y; Hasegawa, M; Matsunaga, K; Murakami, K; Nabeshima, K; Nakai, S; Tomita, M; Yamakita, T, 2010) |
| "Children with refractory epilepsy who are co-treated with the ketogenic diet (KD) and carbonic anhydrase inhibitor (CA-I) anti-epileptic medications including topiramate (TPM) and zonisamide (ZNS) are at risk for urolithiasis." | 7.76 | Urolithiasis on the ketogenic diet with concurrent topiramate or zonisamide therapy. ( Conant, KD; Dunne, IE; Linshaw, MA; Lyczkowski, DA; Paul, E; Pfeifer, HH; Thiele, EA, 2010) |
| "To investigate the impact of zonisamide (ZNS) on body weight in patients with epilepsy." | 7.75 | The impact of zonisamide on weight. A clinical study in 103 patients with epilepsy. ( Bauer, J; Wellmer, J; Wellmer, S, 2009) |
| "Zonisamide (ZNS) is an antiepileptic drug (AED) with broad spectrum action that demonstrated a good efficacy in controlling seizures as add-on in adult and pediatric epilepsy." | 7.75 | Efficacy and tolerability of zonisamide as add-on in brain tumor-related epilepsy: preliminary report. ( Carapella, CM; Dinapoli, L; Jandolo, B; Maschio, M; Pompili, A; Saveriano, F; Vidiri, A, 2009) |
| "We evaluated our clinical experience with zonisamide, a broad-spectrum antiepileptic drug, in a group of children with predominantly medically refractory epilepsy." | 7.73 | Clinical experience with zonisamide monotherapy and adjunctive therapy in children with epilepsy at a tertiary care referral center. ( Aldridge, J; Kim, HL; Rho, JM, 2005) |
| "This study evaluated the effect of the addition of zonisamide on valproic acid (valproate sodium) pharmacokinetics under steady-state conditions in patients with epilepsy." | 7.73 | Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy. ( Brodie, M; Grundy, JS; Levy, RH; Ragueneau-Majlessi, I; Shah, J; Smith, D, 2005) |
| " When zonisamide was administered to a five-year-old girl with intractable epilepsy, disappearance of seizures was accompanied by severe psychotic episodes such as communication disturbance, personal relationship failure, and stereotyped behavior, which continued after the withdrawal of zonisamide." | 7.72 | [A five-year-old girl with epilepsy showing forced normalization due to zonisamide]. ( Haginoya, K; Hirose, M; Iinuma, K; Yokoyama, H, 2003) |
| "Zonisamide (1,2-benzisoxazole-3-methanesulfonamide) is a novel anti-seizure medication approved for use in the United States as adjunct therapy in the treatment of partial seizures in adults with epilepsy." | 7.72 | Utilization of zonisamide in patients with chronic pain or epilepsy refractory to other treatments: a retrospective, open label, uncontrolled study in a VA hospital. ( Hasegawa, H, 2004) |
| "A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide." | 7.69 | Heat stroke-like episode in a child caused by zonisamide. ( Kato, H; Matsuishi, T; Ohnishi, A; Satoi, M; Shimizu, T; Togo, A; Wada, N; Yamashita, Y, 1997) |
| "Seizure frequency (seizures/month; sz/m), blood tests including concentrations of ZNS and β-hydroxybutyric acid, and owner's visual analogue scale score were collected from all dogs for both treatment periods." | 7.30 | Efficacy evaluation of a commercially available MCT enriched therapeutic diet on dogs with idiopathic epilepsy treated with zonisamide: a prospective, randomized, double-blinded, placebo-controlled, crossover dietary preliminary study. ( Hasegawa, D; Nakatsuka, K; Zanghi, B, 2023) |
| "To determine the prevalence of renal calculi in patients treated with zonisamide during randomized, controlled and open-label clinical trials, and from post-marketing surveillance data." | 6.73 | Zonisamide and renal calculi in patients with epilepsy: how big an issue? ( Wroe, S, 2007) |
| "Zonisamide is a new drug with broad-spectrum antiepileptic activity against partial as well as generalized seizures." | 6.69 | Long-term effects of zonisamide in the treatment of epilepsy in children with intellectual disability. ( Cho, K; Iinuma, K; Kajii, N; Minami, T; Tachi, N, 1998) |
| "Zonisamide is a broad spectrum antiepileptic drug with multiple mechanisms of action which has been recently approved in the US and Europe as an adjunctive therapy for refractory partial seizures in adults." | 6.47 | Drug safety evaluation of zonisamide for the treatment of epilepsy. ( Cincotta, M; Tramacere, L; Zaccara, G, 2011) |
| "Zonisamide is an antiepileptic drug used as adjunctive therapy for refractory partial seizures in adults." | 6.43 | Zonisamide: review of its use in epilepsy therapy. ( Zareba, G, 2005) |
| "Zonisamide is a 1,2 benzisoxazole derivative and the first agent of this chemical class to be developed as an antiepileptic drug." | 6.38 | Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy. ( Peters, DH; Sorkin, EM, 1993) |
| "Persistent migraine aura without infarction is a rare but debilitating condition." | 5.62 | Zonisamide as treatment option in persistent migraine aura. ( Broessner, G; Frank, F; Kaltseis, K, 2021) |
| "It is successfully used in treatment of epilepsy for 30 years." | 5.51 | [A retrospective analysis of using zonisamide and retention in monotherapy among patients with epilepsy in routine clinical practice]. ( Belova, YA; Kotov, AS; Romanova, MV; Rudakova, IG, 2019) |
| "Treatment with zonisamide is well tolerated and is not known to be associated with clinically significant drug-drug interactions, including with oral contraceptives or other antiepileptic drugs." | 5.42 | Zonisamide: Review of Recent Clinical Evidence for Treatment of Epilepsy. ( Chen, TC; Chuang, YC; Dash, A; Huang, CW; Jou, SB; Kwan, SY, 2015) |
| "Participants with focal epilepsy were randomised to receive lamotrigine, levetiracetam or zonisamide." | 5.41 | Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs. ( Appleton, R; Baker, G; Balabanova, S; Brown, R; Burnside, G; Hindley, D; Howell, S; Hughes, DA; Leach, JP; Maguire, M; Marson, AG; Mohanraj, R; Plumpton, CO; Sills, G; Smith, D; Smith, PE; Taylor, C; Tudur-Smith, C; Williamson, PR, 2021) |
| " Assessments included treatment-emergent adverse events (TEAEs), clinical laboratory parameters and weight change." | 5.39 | Safety and tolerability of zonisamide in elderly patients with epilepsy. ( Giorgi, L; Patten, A; Segieth, J; Trinka, E, 2013) |
| " Since psychiatric adverse effects, including mania, psychosis, and suicidal ideation, have been associated with its use, it was suggested that the presence of antecedent psychiatric disorders is an important factor associated with the discontinuation of zonisamide therapy in patients with epilepsy." | 5.39 | Psychiatric adverse effects of zonisamide in patients with epilepsy and mental disorder comorbidities. ( Cavanna, AE; Seri, S, 2013) |
| " The present study was aimed to investigate the potential effects of pregnancy on the pharmacokinetic profile of zonisamide (ZNM) in the rabbit." | 5.39 | Impact of pregnancy on zonisamide pharmacokinetics in rabbits. ( Matar, KM, 2013) |
| "Zonisamide (ZNS) is an antiepileptic drug (AED) with multiple putative mechanisms of action." | 5.37 | The long-term retention of zonisamide in a large cohort of people with epilepsy at a tertiary referral centre. ( Bartolini, E; Bell, GS; Catarino, CB; Duncan, JS; Sander, JW; Yuen, AW, 2011) |
| "Zonisamide is a broad-spectrum antiepilepsy drug indicated for the adjunctive treatment of partial seizures in adults." | 5.33 | Zonisamide monotherapy for epilepsy in children and young adults. ( Wilfong, AA, 2005) |
| "Zonisamide (ZNS) was partially effective for the former seizures, and propranolol for the latter." | 5.31 | [Urolithiasis induced by combined ACTH and zonisamide treatment in a patient with startle induced epilepsy]. ( Hayashi, K; Jo, K; Katsumori, H; Nagafuchi, H; Oguni, H; Osawa, M; Saito, Y; Yanagaki, S, 2002) |
| "Anencephaly was detected in one case at 16 weeks of gestation (case 1, artificial abortion), and atrial septal defect was detected in another case at 37 weeks of gestation (case 2, delivery by cesarean section)." | 5.29 | Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy. ( Amano, Y; Egawa, I; Kaneko, S; Kondo, T, 1996) |
| "Zonisamide was found to reduce the behavioral severity of seizure responses to photic stimulation in a dose-related manner." | 5.28 | Effect of a novel anticonvulsant, zonisamide (AD-810, CI-912), in an experimental model of photosensitive epilepsy. ( Hasegawa, H; Wada, Y; Yamaguchi, N, 1990) |
| "Based on these results, zonisamide monotherapy is effective in some dogs with idiopathic epilepsy." | 5.16 | Zonisamide monotherapy for idiopathic epilepsy in dogs. ( Ahn, JO; Chae, JS; Chung, JY; Hwang, CY; Kim, TH; Lee, SY; Seo, KW; Youn, HY, 2012) |
| "To evaluate the effectiveness of zonisamide (ZNS) as monotherapy in children with newly diagnosed epilepsy." | 5.15 | Comparative trial of low- and high-dose zonisamide as monotherapy for childhood epilepsy. ( Chung, HJ; Eom, S; Eun, BL; Eun, SH; Kang, HC; Kim, DW; Kim, HD; Kim, JS; Lee, IK; Lee, JS; Lee, YM; Moon, HK; Suh, ES, 2011) |
| "To report on the first multicenter Italian experience with zonisamide as an add-on drug for refractory generalised or partial epilepsy in children, adolescents and young adults." | 5.14 | Zonisamide in children and young adults with refractory epilepsy: an open label, multicenter Italian study. ( Balestri, P; Coppola, G; Curatolo, P; Franzoni, E; Grosso, S; Iannetti, P; Luchetti, A; Mangano, S; Operto, FF; Parisi, P; Pascotto, A; Pelliccia, A; Verrotti, A, 2009) |
| "This study investigated the efficacy and safety of zonisamide (ZNS) adjunctive therapy in children with intractable epilepsy to existing antiepileptic drugs (AEDs)." | 5.14 | Efficacy and tolerability of adjunctive therapy with zonisamide in childhood intractable epilepsy. ( Kang, HC; Kim, HD; Lee, JS; Lee, YJ; Seo, JH, 2010) |
| "Zonisamide treatment was generally well tolerated and was associated with significant reductions in seizure frequency in this pediatric population with a variety of both partial and generalized medically refractory epilepsy syndromes." | 5.14 | Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy. ( Conry, JA; Pellock, JM; Shinnar, S, 2009) |
| "This study was a prospective, randomized, open-label investigation of the long-term effects of zonisamide (ZNS) monotherapy on cognition and mood of patients with epilepsy." | 5.13 | Long-term cognitive and mood effects of zonisamide monotherapy in epilepsy patients. ( Hwang, YH; Kwon, SH; Lee, BI; Lee, HW; Park, SP; Suh, CK, 2008) |
| "Investigation of the efficacy of zonisamide as an add-on therapy in dogs with refractory epilepsy." | 5.12 | Prospective study of zonisamide therapy for refractory idiopathic epilepsy in dogs. ( Rambeck, B; Tipold, A; von Klopmann, T, 2007) |
| "This study was designed to assess the safety of 25- and 50-mg dosage strengths of zonisamide for initial titration in patients with epilepsy." | 5.11 | Safety of 25- and 50-mg capsules in the initiation of zonisamide therapy in patients with epilepsy: an uncontrolled, open-label study. ( Anthony, S; James, SP; Miller, GS; Montouris, G; Uthman, BM, 2004) |
| "This study was designed to measure the effect of the addition of zonisamide on phenytoin pharmacokinetics under steady-state conditions in patients with epilepsy." | 5.11 | Lack of a clinically significant effect of zonisamide on phenytoin steady-state pharmacokinetics in patients with epilepsy. ( Garnett, WR; Levy, RH; Pan, WJ; Ragueneau-Majlessi, I; Rosenfeld, W; Schmerler, M; Shah, J, 2004) |
| "Clinical effects and pharmacokinetics of once-a-day pediatric zonisamide (ZNS) monotherapy were investigated in 72 children (range, 3 months to 15 years; mean age, 8 years and 3 months) with cryptogenic localization-related epilepsies with simple, complex, or secondarily generalized partial seizures; none had prior epilepsy treatment." | 5.11 | Zonisamide monotherapy with once-daily dosing in children with cryptogenic localization-related epilepsies: clinical effects and pharmacokinetic studies. ( Miura, H, 2004) |
| "Postmarketing data about the effectiveness of zonisamide in childhood epilepsy was collected from 759 children with various forms of epilepsy (ages 3 months-15 years) to compare the long-term efficacy of zonisamide in the treatment of epilepsy in intellectually normal versus intellectually disabled children." | 5.11 | Clinical efficacy of zonisamide in childhood epilepsy after long-term treatment: a postmarketing, multi-institutional survey. ( Haginoya, K; Iinuma, K, 2004) |
| "This study examined the efficacy and safety of zonisamide as monotherapy in pediatric patients with epilepsy." | 5.11 | Effects of zonisamide monotherapy in children with epilepsy. ( Kumagai, N; Maezawa, M; Seki, T, 2004) |
| "The present study was designed to assess the effect of the addition of zonisamide (ZNS) on lamotrigine (LTG) disposition and the safety of the combination under steady-state conditions in patients with epilepsy." | 5.11 | Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy. ( Brodie, MJ; Levy, RH; Pan, WJ; Ragueneau-Majlessi, I; Shah, J; Smith, DF, 2005) |
| "Zonisamide (ZNS), a second-generation antiepileptic drug, indicated as add-on treatment of focal epilepsy, has been recently approved as monotherapy for the treatment of partial seizures in adults affected by newly diagnosed epilepsy in Europe." | 4.91 | Zonisamide in the management of epilepsy in the elderly. ( Di Gennaro, G; Fattore, C; Femia, EA; Franco, V; Romigi, A; Vitrani, G, 2015) |
| "This literature review is devoted to the use of the antiepileptic drug zonisamide in the initial monotherapy of symptomatic and cryptogenic partial epilepsy." | 4.91 | [New possibilities of monotherapy of symptomatic and cryptogenic partial epilepsy]. ( Belova, YA; Rudakova, IG, 2015) |
| "At this moment, zonisamide represents a robust option in the treatment of a large number of patients with epilepsy, based on its multiple mechanism of action and efficacy in different situations." | 4.89 | [Zonisamide in the epilepsy treatment: a literature review from add-on therapy to monotherapy]. ( Serrano-Castro, PJ; Villanueva, V, 2013) |
| "From the available clinical data, zonisamide is a viable first-line and adjunctive therapeutic for partial-onset epilepsy and should be considered as an adjunctive therapeutic for a wide-range of generalized epilepsies." | 4.87 | Zonisamide in the treatment of epilepsy. ( Holder, JL; Wilfong, AA, 2011) |
| " Zonisamide is an antiepileptic drug with multiple mechanisms of action, corresponding to efficacy in diverse epilepsy syndromes." | 4.86 | Zonisamide in the treatment of epilepsy. ( Schulze-Bonhage, A, 2010) |
| " It is unclear whether or not monotherapy with the new AEDs offers higher efficacy and/or lower side effects compared to classic AEDs (phenobarbital, phenytoin, carbamazepine, or valproate) thereby significantly improving the quality of life in children with epilepsy." | 4.85 | [Role of monotherapy with new antiepileptic drugs in the treatment of childhood epilepsy]. ( Legido, A; Valencia, I, 2009) |
| "On the basis of six randomized controlled trials, zonisamide (ZNS) can be prescribed as add-on treatment in focal adulthood epilepsy in USA and Europe." | 4.85 | [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases]. ( Janszky, J, 2009) |
| " The USA guideline for epilepsy treatment recommends that patients with newly diagnosed epilepsy can be treated with gabapentin, lamotrigine, topiramate, and oxcarbazepine." | 4.84 | [Newer antiepileptic drugs]. ( Matsuura, M, 2007) |
| " Zonisamide is the latest addition to the pharmacological management of epilepsy in Europe, following extensive clinical experience in Japan and the USA." | 4.83 | Zonisamide for the treatment of epilepsy. ( Arzimanoglou, A; Rahbani, A, 2006) |
| "The introduction of these new antiepileptic drugs, from felbamate to levetiracetam, raised hope of control of epilepsy with fewer adverse effects and improved quality of life." | 4.81 | New antiepileptic drug therapies. ( Bergin, AM; Connolly, M, 2002) |
| "Zonisamide is a novel anticonvulsant that is structurally and mechanistically unique, compared with other antiepilepsy drugs." | 4.81 | Zonisamide in pediatric epilepsy: review of the Japanese experience. ( Glauser, TA; Pellock, JM, 2002) |
| "Zonisamide (ZNS) is a broad-spectrum antiepileptic drug in both animal models of epilepsy and patients with epilepsy." | 4.80 | Zonisamide. ( Leppik, IE, 1999) |
| "A brief review of epilepsy as a disease, anti-epileptic drugs and methods of evaluation of anti-epileptic drugs are presented as a background for assessment of zonisamide, which has been approved by the FDA as add-on therapy for the treatment of partial seizures with or without secondary generalisation in adults." | 4.80 | An assessment of zonisamide as an anti-epileptic drug. ( Jain, KK, 2000) |
| "To evaluate the efficacy and tolerability of the newly developed antiepileptic drugs gabapentin, lamotrigine, tiagabine, topiramate, vigabatrin, and zonisamide in patients with refractory partial epilepsy." | 4.79 | New antiepileptic drugs: a systematic review of their efficacy and tolerability. ( Chadwick, DW; Kadir, ZA; Marson, AG, 1996) |
| "Gabapentin, lamotrigine, tiagabine, topiramate, vigabatrin, and zonisamide are all administered as add-on therapy for treatment of patients with refractory epilepsy." | 4.79 | Clinical administration of new antiepileptic drugs: an overview of safety and efficacy. ( Chadwick, DW; Kadir, Z; Marson, T, 1996) |
| "Gabapentin (GBP), lamotrigine (LTG), tiagabine (TGB), topiramate (TPM), vigabatrin (VGB), and zonisamide (ZNS) are all in use as "add-on" treatment for patients with refractory epilepsy." | 4.79 | The new antiepileptic drugs: a systematic review of their efficacy and tolerability. ( Chadwick, DW; Hutton, JL; Kadir, ZA; Marson, AG, 1997) |
| "To investigate caregivers' assessments of outcome in dogs with idiopathic epilepsy (IE) administered levetiracetam (LEV), zonisamide (ZNS), or phenobarbital (PB) monotherapy." | 4.31 | Comparison of caregivers' assessments of clinical outcome in dogs with idiopathic epilepsy administered levetiracetam, zonisamide, or phenobarbital monotherapy. ( Gristina, BR; Muñana, KR; Nettifee, JA; Waldron, RJ, 2023) |
| "To assess the therapeutic efficacy and safety of antiseizure medication (ASM) for a minimum of 6 months, including zonisamide (ZNS), in feline idiopathic epilepsy at a referral hospital in Japan." | 4.31 | Evaluation of antiseizure medications including zonisamide in feline idiopathic epilepsy at a referral hospital in Japan. ( Maeda, S; Motegi, T; Yonezawa, T; Yoshida, S, 2023) |
| "Based on these data, lacosamide and eslicarbazepine might be more favorable in the treatment of refractory status epilepticus in poststroke epilepsy, when administered as second- or third-line ASMs before anesthesia." | 4.31 | Third-Generation Antiseizure Medication in the Treatment of Benzodiazepine-Refractory Status Epilepticus in Poststroke Epilepsy: A Retrospective Observational Register-Based Study. ( Gonzalez-Escamilla, G; Groppa, S; Sandner, K; Stuckrad-Barre, SV; Vieth, T; Winter, Y, 2023) |
| "Zonisamide (ZNS) is a new generation antiepileptic drug (AED) used in refractory epilepsy." | 4.12 | Effectiveness of zonisamide in childhood refractory epilepsy. ( Aslan, M; Gungor, S, 2022) |
| "A 3-year-old neutered male golden retriever administered zonisamide for the treatment of seizures showed lethargy and had normal anion gap metabolic acidosis with hypokalaemia, hyperchloremia, and alkaline urine." | 4.12 | Distal renal tubular acidosis and lethargy associated with zonisamide treatment in a dog with idiopathic epilepsy. ( Akashi, N; Hata, A; Itoi, T; Kanda, T; Kutara, K; Miyama, TS; Shimizu, Y; Sugimoto, K, 2022) |
| "Animal data suggest teratogenic effects with zonisamide use and risk of pregnancy losses." | 4.02 | Zonisamide safety in pregnancy: Data from the UK and Ireland epilepsy and pregnancy register. ( Bromley, R; Campbell, E; Craig, JJ; Delanty, N; Heath, C; Hunt, SJ; Irwin, B; Kinney, MO; Liggan, B; MacKillop, L; McCluskey, G; Morrison, PJ; Morrow, J; Murphy, S; Parsons, L; Russell, A; Smithson, WH, 2021) |
| "We aim to evaluate the impact of zonisamide (ZNS) compared to topiramate (TPM) on cognition in patients with epilepsy." | 3.96 | Changes in cognition after introduction or withdrawal of zonisamide versus topiramate in epilepsy patients: A retrospective study using Bayes statistics. ( Brömling, S; Helmstaedter, C; Meschede, C; Moskau-Hartmann, S; Rademacher, M; Surges, R; von Wrede, R; Witt, JA, 2020) |
| "Objectives The effectiveness of zonisamide (ZNS) against spontaneous epilepsy in cats has not yet been described." | 3.88 | Efficacy of zonisamide on interictal electroencephalography in familial spontaneous epileptic cats. ( Fujita, M; Fujiwara-Igarashi, A; Hamamoto, Y; Hasegawa, D; Ukai, M; Yu, Y, 2018) |
| "The present findings revealed that zonisamide treatment prevented the development of seizures in animals." | 3.88 | A mechanistic approach to explore the neuroprotective potential of zonisamide in seizures. ( Attri, SV; Kumar, B; Medhi, B; Modi, M; Patial, A; Saikia, B, 2018) |
| "To investigate the change in zonisamide (ZNS) serum concentration and its consequences in pregnant women with epilepsy." | 3.88 | Zonisamide serum concentrations during pregnancy. ( Aurlien, D; Becser Andersen, N; Brodtkorb, E; Christensen, J; Haggag, K; Helde, G; Lillestølen, KM; Nakken, KO; Reimers, A; Surlien Navjord, E, 2018) |
| " On referral, treatment with levetiracetam, zonisamide, and phenobarbital initially provided good control of cluster seizure activity (attributable to epilepsy of unknow origin)." | 3.85 | Suspected zonisamide-related anticonvulsant hypersensitivity syndrome in a cat. ( Collinet, A; Sammut, V, 2017) |
| "Zonisamide is licensed for adjunctive therapy for partial-onset seizures with or without secondary generalisation in patients 6 years and older and as monotherapy for the treatment of partial seizures in adult patients with newly diagnosed epilepsy, and shows a favourable pharmacokinetic profile with low interaction potential with other drugs." | 3.83 | Retention, dosing, tolerability and patient reported seizure outcome of Zonisamide as only add-on treatment under real-life conditions in adult patients with partial onset seizures: Results of the observational study ZOOM. ( Baulac, M; Hamer, H; Kockelmann, E; McMurray, R, 2016) |
| "Although it has been reported that some antiepileptic drugs have inducing or inhibiting effects on lamotrigine (LTG) clearance, whether they have the same effects in Asian epilepsy patients as in those in other countries has not been clarified, especially in children." | 3.83 | The effects of co-medications on lamotrigine clearance in Japanese children with epilepsy. ( Abe, S; Azuma, Y; Ishihara, N; Ito, Y; Itomi, K; Kidokoro, H; Kojima, S; Kurahashi, H; Kurahashi, N; Maruyama, K; Natsume, J; Negoro, T; Okumura, A; Suzuki, M; Takeuchi, T; Tsuji, T; Watanabe, K; Yamada, K; Yamamoto, H, 2016) |
| "To assess the effect and tolerability of zonisamide (ZNS) as adjunctive treatment for difficult-to-treat epilepsy in adult Scandinavian patients." | 3.81 | Retention rate of zonisamide in intractable epilepsy. ( Andersen, H; Lindstrøm, P; Nakken, KO, 2015) |
| "This report describes a dog that developed erythema multiforme in temporal association with administration of the sulphonamide-based anticonvulsant drug zonisamide." | 3.81 | Erythema multiforme associated with zonisamide in a dog. ( Ackermann, AL; Frank, LA; May, ER; McEntee, MF, 2015) |
| " Zonisamide is approved for the treatment of partial onset epilepsy, and is used in practice for both generalized and partial onset epilepsy." | 3.81 | Safety and tolerability of an oral zonisamide loading dose. ( Bazil, CW; Jongeling, AC; Richins, RJ, 2015) |
| "To further assess the safety of adjunctive zonisamide in paediatric epilepsy patients." | 3.80 | Safety and tolerability of zonisamide in paediatric patients with epilepsy. ( Auvin, S; Cross, JH; Giorgi, L; Patten, A, 2014) |
| "Zonisamide is a new generation antiepileptic drug (AED) widely used in children with refractory epilepsy, although until recently, it was used to a large extent as off-label or unlicensed medication due to the lack of evidence-based studies." | 3.80 | Zonisamide: pharmacokinetics, efficacy, and adverse events in children with epilepsy. ( Dahlin, M; Ohman, I; Wallander, KM, 2014) |
| "In everyday practice, zonisamide is principally used in association with other antiepileptic drugs for the treatment of focal epilepsy in adults." | 3.79 | Management and monitoring of patients treated with zonisamide: the OZONE study. ( Allaf, B; Biraben, A; Dupont, S; Lavernhe, G; Marquet, T, 2013) |
| " We performed an open-label, observational study to assess the effects of zonisamide on weight in overweight female epilepsy patients." | 3.78 | Low serum leptin level is associated with zonisamide-induced weight loss in overweight female epilepsy patients. ( Kim, DW; Park, KS; Yoo, MW, 2012) |
| "Concerning zonisamide (ZNS) therapy, data on sexual dysfunction are not available either in patients with epilepsy or in patients with brain tumor-related epilepsy." | 3.77 | Reversible erectile dysfunction in a patient with brain tumor-related epilepsy in therapy with zonisamide in add-on. ( Dinapoli, L; Jandolo, B; Maschio, M; Saveriano, F, 2011) |
| "A 9-year old female spayed Rottweiler was diagnosed with cryptogenic epilepsy and started on zonisamide monotherapy (8." | 3.77 | Possible drug-induced hepatopathy in a dog receiving zonisamide monotherapy for treatment of cryptogenic epilepsy. ( Muñana, KR; Olby, NJ; Schwartz, M, 2011) |
| "To evaluate the effectiveness and tolerability of zonisamide in children with epilepsy." | 3.76 | Effectiveness and tolerability of zonisamide in children with epilepsy: a retrospective review. ( Appleton, RE; Kneen, R; Martland, TR; Tan, HJ, 2010) |
| "We present an implementation of a method we previously reported allowing the newer antiepileptic drugs (AEDs) rufinamide (RFN) and zonisamide (ZNS) to be simultaneously determined with lamotrigine (LTG), oxcarbazepine's (OXC) main active metabolite monohydroxycarbamazepine (MHD) and felbamate (FBM) in plasma of patients with epilepsy using high performance liquid chromatography (HPLC) with UV detection." | 3.76 | Simultaneous HPLC-UV analysis of rufinamide, zonisamide, lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in deproteinized plasma of patients with epilepsy. ( Albani, F; Baruzzi, A; Candela, C; Contin, M; Mohamed, S; Riva, R, 2010) |
| " The current report describes a man who was prescribed zonisamide for epilepsy and subsequently developed widespread skin rash, acute kidney injury, high-grade fever, eosinophilia, liver dysfunction, lymphadenopathy and an increase in antihuman herpesvirus-6 immunoglobulin G titer." | 3.76 | Acute kidney injury caused by zonisamide-induced hypersensitivity syndrome. ( Fujita, Y; Hasegawa, M; Matsunaga, K; Murakami, K; Nabeshima, K; Nakai, S; Tomita, M; Yamakita, T, 2010) |
| "Children with refractory epilepsy who are co-treated with the ketogenic diet (KD) and carbonic anhydrase inhibitor (CA-I) anti-epileptic medications including topiramate (TPM) and zonisamide (ZNS) are at risk for urolithiasis." | 3.76 | Urolithiasis on the ketogenic diet with concurrent topiramate or zonisamide therapy. ( Conant, KD; Dunne, IE; Linshaw, MA; Lyczkowski, DA; Paul, E; Pfeifer, HH; Thiele, EA, 2010) |
| "To investigate the impact of zonisamide (ZNS) on body weight in patients with epilepsy." | 3.75 | The impact of zonisamide on weight. A clinical study in 103 patients with epilepsy. ( Bauer, J; Wellmer, J; Wellmer, S, 2009) |
| "Zonisamide (ZNS) is an antiepileptic drug (AED) with broad spectrum action that demonstrated a good efficacy in controlling seizures as add-on in adult and pediatric epilepsy." | 3.75 | Efficacy and tolerability of zonisamide as add-on in brain tumor-related epilepsy: preliminary report. ( Carapella, CM; Dinapoli, L; Jandolo, B; Maschio, M; Pompili, A; Saveriano, F; Vidiri, A, 2009) |
| "We evaluated our clinical experience with zonisamide, a broad-spectrum antiepileptic drug, in a group of children with predominantly medically refractory epilepsy." | 3.73 | Clinical experience with zonisamide monotherapy and adjunctive therapy in children with epilepsy at a tertiary care referral center. ( Aldridge, J; Kim, HL; Rho, JM, 2005) |
| "This study evaluated the effect of the addition of zonisamide on valproic acid (valproate sodium) pharmacokinetics under steady-state conditions in patients with epilepsy." | 3.73 | Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy. ( Brodie, M; Grundy, JS; Levy, RH; Ragueneau-Majlessi, I; Shah, J; Smith, D, 2005) |
| "Long-term zonisamide monotherapy was efficacious in a wide range of patients with epilepsy." | 3.73 | A long-term follow-up of zonisamide monotherapy. ( Fukushima, K; Seino, M, 2006) |
| " When zonisamide was administered to a five-year-old girl with intractable epilepsy, disappearance of seizures was accompanied by severe psychotic episodes such as communication disturbance, personal relationship failure, and stereotyped behavior, which continued after the withdrawal of zonisamide." | 3.72 | [A five-year-old girl with epilepsy showing forced normalization due to zonisamide]. ( Haginoya, K; Hirose, M; Iinuma, K; Yokoyama, H, 2003) |
| "Zonisamide (1,2-benzisoxazole-3-methanesulfonamide) is a novel anti-seizure medication approved for use in the United States as adjunct therapy in the treatment of partial seizures in adults with epilepsy." | 3.72 | Utilization of zonisamide in patients with chronic pain or epilepsy refractory to other treatments: a retrospective, open label, uncontrolled study in a VA hospital. ( Hasegawa, H, 2004) |
| "Zonisamide is widely used for intractable epilepsy and the effects of this drug on fetuses and neonates through the mother taking it for epilepsy need to be clarified." | 3.71 | Pharmacokinetics of zonisamide in perinatal period. ( Ishii, M; Isobe, K; Itoh, S; Kawada, K; Kusaka, T, 2002) |
| "We investigated the effects of zonisamide, a new antiepileptic drug, on voltage-dependent T-type calcium current (ICa) in cultured neuroblastoma cells of human origin (NB-I)." | 3.69 | Mechanisms of T-type calcium channel blockade by zonisamide. ( Kito, M; Maehara, M; Watanabe, K, 1996) |
| "A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide." | 3.69 | Heat stroke-like episode in a child caused by zonisamide. ( Kato, H; Matsuishi, T; Ohnishi, A; Satoi, M; Shimizu, T; Togo, A; Wada, N; Yamashita, Y, 1997) |
| " The guidelines for clinical evaluation of antiepileptic drugs (AEDs), proposed by the International League Against Epilepsy in 1989, were scrutinized through our clinical experiences with zonisamide." | 3.68 | Methodological requirements for clinical trials in refractory epilepsies--our experience with zonisamide. ( Seino, M; Yagi, K, 1992) |
| "Zonisamide (AD-810) was additionally administered to 19 patients with refractory epilepsy who had been receiving multiple antiepileptic drugs and the effect of zonisamide on serum immunoglobulins was investigated." | 3.68 | Effect of zonisamide on serum immunoglobulins. ( Fujimoto, Y; Ikoma, R; Shimizu, A; Shimizu, T, 1990) |
| "Seizure frequency (seizures/month; sz/m), blood tests including concentrations of ZNS and β-hydroxybutyric acid, and owner's visual analogue scale score were collected from all dogs for both treatment periods." | 3.30 | Efficacy evaluation of a commercially available MCT enriched therapeutic diet on dogs with idiopathic epilepsy treated with zonisamide: a prospective, randomized, double-blinded, placebo-controlled, crossover dietary preliminary study. ( Hasegawa, D; Nakatsuka, K; Zanghi, B, 2023) |
| "To determine the prevalence of renal calculi in patients treated with zonisamide during randomized, controlled and open-label clinical trials, and from post-marketing surveillance data." | 2.73 | Zonisamide and renal calculi in patients with epilepsy: how big an issue? ( Wroe, S, 2007) |
| " At that point in time the mean ZNS dosage was 344 mg and mean TPM dosage was 398 mg." | 2.73 | [Anticonvulsant treatment with zonisamide added to topiramate. A preliminary treatment analysis in 19 patients]. ( Bauer, J; Bös, M, 2007) |
| "Zonisamide monotherapy was well tolerated." | 2.71 | Zonisamide monotherapy in a multi-group clinic. ( Dubinsky, S; Newmark, ME, 2004) |
| "Zonisamide was highly effective for treating partial seizures, with 70% of patients reporting improvement." | 2.71 | Efficacy of zonisamide: our experience. ( Aikawa, H; Yamauchi, T, 2004) |
| " Median zonisamide maintenance dosage was 400mg/day, and the average therapeutic blood level was 16." | 2.71 | Zonisamide clinical trials: European experience. ( Brodie, MJ, 2004) |
| " Based on the lack of clinically relevant in vitro and in vivo effects, adjustment of carbamazepine dosing should not be required with concomitant zonisamide administration." | 2.71 | Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients. ( Bergen, D; Garnett, W; Grundy, JS; Levy, RH; Mather, G; Ragueneau-Majlessi, I; Rosenfeld, W; Shah, J, 2004) |
| "Zonisamide is a new drug with broad-spectrum antiepileptic activity against partial as well as generalized seizures." | 2.69 | Long-term effects of zonisamide in the treatment of epilepsy in children with intellectual disability. ( Cho, K; Iinuma, K; Kajii, N; Minami, T; Tachi, N, 1998) |
| " Adverse effects involved principally the CNS and were similar to those seen with other antiepileptic drugs." | 2.67 | Efficacy and safety of zonisamide: results of a multicenter study. ( Fromm, G; Homan, RW; Leppik, IE; Lesser, RP; Oommen, KJ; Penry, JK; Sackellares, JC; Smith, DB; Wallace, JD; Willmore, LJ, 1993) |
| "Epilepsy is a common neurological condition with a worldwide prevalence of around 1%." | 2.55 | Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. ( Marson, AG; Nevitt, SJ; Sudell, M; Tudur Smith, C; Weston, J, 2017) |
| "Epilepsy is a common neurological condition with a worldwide prevalence of around 1%." | 2.55 | Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. ( Marson, AG; Nevitt, SJ; Sudell, M; Tudur Smith, C; Weston, J, 2017) |
| "Epilepsy is one of the most common neurological conditions in the elderly, and the incidence of de novo geriatric epilepsy is rising." | 2.49 | [Epilepsy in the elderly]. ( Lossius, MI; Markhus, R; Nakken, KO; Sætre, E, 2013) |
| "The first aim of our study was to analyze the adverse events statistically significantly associated with zonisamide, through a systematic review and meta-analysis of available randomized placebo-controlled trials (RCTs)." | 2.49 | The adverse event profile of zonisamide: a meta-analysis. ( Di Sabatino, F; Loiacono, G; Verrotti, A; Zaccara, G, 2013) |
| "Zonisamide displays predictable, dose-dependent pharmacokinetics and has a half-life of ~60 h, allowing once- or twice-daily administration." | 2.48 | Zonisamide: its pharmacology, efficacy and safety in clinical trials. ( Ben-Menachem, E; Brodie, MJ; Chouette, I; Giorgi, L, 2012) |
| "Zonisamide is a broad spectrum antiepileptic drug with multiple mechanisms of action which has been recently approved in the US and Europe as an adjunctive therapy for refractory partial seizures in adults." | 2.47 | Drug safety evaluation of zonisamide for the treatment of epilepsy. ( Cincotta, M; Tramacere, L; Zaccara, G, 2011) |
| " Older-generation antiepileptic drugs (AEDs) are well known for their pharmacokinetic interaction potential, which generally results from alterations in the metabolism of concomitant drugs due to effects on the cytochrome P450 (CYP) and uridine glucuronyl transferase enzyme systems." | 2.44 | Pharmacokinetics and drug interactions with zonisamide. ( Brodie, M; Sills, G, 2007) |
| "A review of the pharmacokinetics, pharmacodynamics, evidence for efficacy in different seizure types and non-seizure conditions, adverse effects, and tolerability of ZNS is presented." | 2.44 | Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. ( Kaleyias, J; Kothare, SV, 2008) |
| "Zonisamide is an antiepileptic drug used as adjunctive therapy for refractory partial seizures in adults." | 2.43 | Zonisamide: review of its use in epilepsy therapy. ( Zareba, G, 2005) |
| " Open-label extension studies in the United States and Europe suggest continued efficacy of zonisamide in long-term treatment without development of adverse events further to those seen in registration studies." | 2.43 | Practical prescribing and long-term efficacy and safety of zonisamide. ( Leppik, IE, 2006) |
| " For drugs that are eliminated renally completely unchanged (gabapentin, pregabalin and vigabatrin) or mainly unchanged (levetiracetam and topiramate), the pharmacokinetic variability is less pronounced and more predictable." | 2.43 | Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? ( Johannessen, SI; Tomson, T, 2006) |
| "The pharmacokinetic properties of a drug are the primary deter-minant of the extent and duration of drug action, and influence susceptibility to clinically important drug interactions." | 2.42 | The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come? ( Johannessen, SI; Perucca, E, 2003) |
| "Vigabatrin has shown promise in treating IS patients, particularly those with tuberous sclerosis." | 2.42 | Pharmacologic treatment of the catastrophic epilepsies. ( Conry, JA, 2004) |
| "Zonisamide is a benzisoxazole-based compound first synthesized in the early 1970s by the research laboratories of Dainippon Pharmaceutical Company in Osaka, Japan." | 2.42 | Review of zonisamide development in Japan. ( Seino, M, 2004) |
| "Zonisamide has multiple mechanisms of action, which may explain widespread reports of its utility in focal epilepsy and generalized epilepsy, and for nonseizure disorders such as headache and neuropathic pain." | 2.42 | Zonisamide: newer antiepileptic agent with multiple mechanisms of action. ( Biton, V, 2004) |
| "Although antiepileptic drugs (AEDs) are commonly used to control and prevent seizures, their long-term use carries a considerable risk of morbidity." | 2.41 | Antiepileptic drug therapy for adults: when to initiate and how to choose. ( Sirven, JI, 2002) |
| "Oxcarbazepine also has approval for monotherapy in partial seizures." | 2.41 | Newer therapies in the drug treatment of epilepsy. ( Biederman, TS; McAuley, JW; Moore, JL; Smith, JC, 2002) |
| " For all drugs that are metabolized, half-life is shortened and clearance is increased when patients receive concomitant enzyme-inducing agents such as barbiturates, phenytoin, and carbamazepine." | 2.40 | The clinical pharmacokinetics of the new antiepileptic drugs. ( Perucca, E, 1999) |
| "Epilepsy is one of the most common neurological disorders." | 2.39 | Newer antiepileptic drugs. Towards an improved risk-benefit ratio. ( Patsalos, PN; Sander, JW, 1994) |
| " ZNS daily dosage is 400-600 mg." | 2.39 | Antiepileptic drugs in development: prospects for the near future. ( Leppik, IE, 1994) |
| "Zonisamide was synthesized by the sulfonation and the successive amination of 1,2-benzisoxazole-3-acetic acid in a very poor yield." | 2.39 | [Research and development of zonisamide, a new type of antiepileptic drug]. ( Ito, T; Kurokawa, M; Masuda, Y; Shimizu, M; Uno, H, 1996) |
| "Zonisamide is a 1,2 benzisoxazole derivative and the first agent of this chemical class to be developed as an antiepileptic drug." | 2.38 | Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy. ( Peters, DH; Sorkin, EM, 1993) |
| "Zonisamide has a broader therapeutic range than other antiepileptic drugs." | 2.37 | Neuropharmacology of zonisamide, a new antiepileptic drug. ( Hammond, EJ; McLean, JR; Perchalski, RJ; Wilder, BJ, 1987) |
| " Therefore, knowledge about the typical adverse events (AEs) for ASMs and other coadministered drugs (CDs) is essential for practitioners and patients." | 1.91 | Adverse Event Profiles of Antiseizure Medications and the Impact of Coadministration on Drug Tolerability in Adults with Epilepsy. ( Knake, S; Kovac, S; Rosenow, F; Strzelczyk, A; van der Goten, M; von Podewils, F; Willems, LM; Zöllner, JP, 2023) |
| "Both the prevalence of treatment for epilepsy and of treatment for psychosis was 0." | 1.72 | Bidirectionality of antiseizure and antipsychotic treatment: A population-based study. ( Bakken, IJ; Bråthen, G; Brodtkorb, E; Landmark, CJ; Morken, G; Revdal, E, 2022) |
| "Early-onset severe spinocerebellar ataxia 42 with neurodevelopmental deficits (SCA42ND, MIM#604065) is an ultrarare autosomal dominant syndrome related to de novo CACNA1G gain-of-function pathogenic variants." | 1.62 | Early-onset severe spinocerebellar ataxia 42 with neurodevelopmental deficits (SCA42ND): Case report, pharmacological trial, and literature review. ( Bolasell, M; Casas-Alba, D; Fernández-Fernández, JM; López-Sala, L; Mari-Vico, R; Martínez-Monseny, AF; Martorell, L; Muchart, J; Pérez-Ordóñez, M; Serrano, M, 2021) |
| "Persistent migraine aura without infarction is a rare but debilitating condition." | 1.62 | Zonisamide as treatment option in persistent migraine aura. ( Broessner, G; Frank, F; Kaltseis, K, 2021) |
| " Age, sex, treatment duration, and ZNS dosage were included as covariates for adjustment in the ANCOVA model." | 1.56 | Effects of zonisamide monotherapy on bone health in drug-naive epileptic patients. ( Koo, DL; Nam, H, 2020) |
| "It is successfully used in treatment of epilepsy for 30 years." | 1.51 | [A retrospective analysis of using zonisamide and retention in monotherapy among patients with epilepsy in routine clinical practice]. ( Belova, YA; Kotov, AS; Romanova, MV; Rudakova, IG, 2019) |
| " A population pharmacokinetic approach and nonlinear mixed effects modeling were used to analyze the data." | 1.48 | Population pharmacokinetics of extended-release levetiracetam in epileptic dogs when administered alone, with phenobarbital or zonisamide. ( Muñana, KR; Nettifee, JA; Otamendi, AJ; Papich, MG, 2018) |
| " Therefore, drug monitoring is necessary for appropriate dosage adjustments." | 1.46 | Chromatographic determination of zonisamide, topiramate and sulpiride in plasma by a fluorescent 'turn-on' chemosensor. ( Barary, MA; El-Yazbi, AF; Ibrahim, FA; Wagih, MM, 2017) |
| "Treatment with zonisamide is well tolerated and is not known to be associated with clinically significant drug-drug interactions, including with oral contraceptives or other antiepileptic drugs." | 1.42 | Zonisamide: Review of Recent Clinical Evidence for Treatment of Epilepsy. ( Chen, TC; Chuang, YC; Dash, A; Huang, CW; Jou, SB; Kwan, SY, 2015) |
| "Hyperammonemia was defined as a plasma ammonia level exceeding 100 μg/dl with reference to the standard range and previous reports." | 1.39 | Risk factors for hyperammonemia in pediatric patients with epilepsy. ( Imai, K; Inoue, K; Inoue, Y; Itoh, K; Kagawa, Y; Mishima, N; Takahashi, Y; Yamamoto, Y; Yazawa, R, 2013) |
| " Assessments included treatment-emergent adverse events (TEAEs), clinical laboratory parameters and weight change." | 1.39 | Safety and tolerability of zonisamide in elderly patients with epilepsy. ( Giorgi, L; Patten, A; Segieth, J; Trinka, E, 2013) |
| " Since psychiatric adverse effects, including mania, psychosis, and suicidal ideation, have been associated with its use, it was suggested that the presence of antecedent psychiatric disorders is an important factor associated with the discontinuation of zonisamide therapy in patients with epilepsy." | 1.39 | Psychiatric adverse effects of zonisamide in patients with epilepsy and mental disorder comorbidities. ( Cavanna, AE; Seri, S, 2013) |
| " The present study was aimed to investigate the potential effects of pregnancy on the pharmacokinetic profile of zonisamide (ZNM) in the rabbit." | 1.39 | Impact of pregnancy on zonisamide pharmacokinetics in rabbits. ( Matar, KM, 2013) |
| "Zonisamide (ZNS) is an antiepileptic drug (AED) with multiple putative mechanisms of action." | 1.37 | The long-term retention of zonisamide in a large cohort of people with epilepsy at a tertiary referral centre. ( Bartolini, E; Bell, GS; Catarino, CB; Duncan, JS; Sander, JW; Yuen, AW, 2011) |
| "Zonisamide (ZNS) is an antiepileptic drug (AED) that has been associated with psychiatric adverse events (PAE) and cognitive adverse events (CAE); controlled studies evaluating these adverse events are limited." | 1.36 | Zonisamide discontinuation due to psychiatric and cognitive adverse events: a case-control study. ( Beniak, TE; Birnbaum, AK; Leppik, IE; Marino, SE; Walczak, TS; White, JR, 2010) |
| "Zonisamide (ZNS) is an anticonvulsant drug known to affect various neuronal channels and transmitter systems." | 1.35 | Antiepileptic activity of zonisamide on hippocampal CA3 neurons does not depend on carbonic anhydrase inhibition. ( Leniger, T; Splettstösser, F; Thöne, J; Wiemann, M, 2008) |
| "Zonisamide (ZNS) is a new AED effective in the treatment of refractory epilepsy and since it is only prescribed in polytherapy regimens, its interactions with other AEDs is of particular importance." | 1.34 | Interactions between zonisamide and conventional antiepileptic drugs in the mouse maximal electroshock test model. ( Borowicz, KK; Czuczwar, SJ; Luszczki, JJ; Patsalos, PN; Ratnaraj, N; Sobieszek, G, 2007) |
| "The etiology of Moebius syndrome remains unknown." | 1.34 | A case of Moebius syndrome presenting with congenital bilateral vocal cord paralysis. ( Arinami, T; Hasegawa, M; Kamoda, T; Kanemoto, K; Kanemoto, N, 2007) |
| "We diagnosed interstitial pneumonitis (IP) based on her chest CT and high serum concentrations of KL-6 and surfactant protein D." | 1.34 | [Valproate sodium and zonisamide associated interstitial pneumonitis in an infant]. ( Doi, T; Kato, T; Nikaido, K; Takayama, R, 2007) |
| "Zonisamide safety was evaluated based on a postmarketing surveillance study of patients treated for 1-3 years." | 1.34 | Erratum to "Safety of zonisamide therapy: prospective follow-up survey.". ( Ohtahara, S; Yamatogi, Y, 2007) |
| " The pharmacokinetics of the 260 PB concentrations at a steady-state obtained from 79 patients was described with a one-compartment open pharmacokinetic model with first-order elimination." | 1.34 | Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese. ( Goto, S; Ishitsu, T; Murata, T; Nakada, N; Nakagawa, K; Seo, T; Ueda, N, 2007) |
| "Zonisamide is a broad-spectrum antiepilepsy drug indicated for the adjunctive treatment of partial seizures in adults." | 1.33 | Zonisamide monotherapy for epilepsy in children and young adults. ( Wilfong, AA, 2005) |
| " Thirty of 112 patients (27%) reported mild to moderate adverse events, such as weight loss (5." | 1.33 | Long-term efficacy and safety of monotherapy and adjunctive therapy with zonisamide. ( Tisdell, J; Tosches, WA, 2006) |
| "Zonisamide is a new type of benzisoxazole derivative, first marketed in Japan in 1989." | 1.32 | Overview of Japanese experience-controlled and uncontrolled trials. ( Yagi, K, 2004) |
| "Zonisamide safety was evaluated based on a postmarketing surveillance study of patients treated for 1-3 years." | 1.32 | Safety of zonisamide therapy: prospective follow-up survey. ( Ohtahara, S; Yamatogi, Y, 2004) |
| "Zonisamide (ZNS) was partially effective for the former seizures, and propranolol for the latter." | 1.31 | [Urolithiasis induced by combined ACTH and zonisamide treatment in a patient with startle induced epilepsy]. ( Hayashi, K; Jo, K; Katsumori, H; Nagafuchi, H; Oguni, H; Osawa, M; Saito, Y; Yanagaki, S, 2002) |
| "If patients with ZNS therapy showed IgA deficiency and recurrent infections, it is preferable to check serum IgG subclass concentrations as well." | 1.30 | IgA and IgG2 deficiency associated with zonisamide therapy: a case report. ( Dejima, S; Hara, T; Maeoka, Y; Takeshita, K, 1997) |
| " The 266 serum concentration data at steady-state after repetitive oral administration were analyzed using the nonlinear mixed effects model (NONMEM) program designed for estimation of population pharmacokinetic parameters." | 1.29 | Population analysis of the dose-dependent pharmacokinetics of zonisamide in epileptic patients. ( Hashimoto, Y; Hori, R; Odani, A; Okuno, T; Tanigawara, Y; Yasuhara, M, 1994) |
| "Anencephaly was detected in one case at 16 weeks of gestation (case 1, artificial abortion), and atrial septal defect was detected in another case at 37 weeks of gestation (case 2, delivery by cesarean section)." | 1.29 | Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy. ( Amano, Y; Egawa, I; Kaneko, S; Kondo, T, 1996) |
| " These results suggest that dosage regimens on the basis of body surface area would be more accurate than those on a body weight basis and that there is little effect of other antiepileptics on the serum protein binding of ZNS." | 1.28 | Factors influencing serum concentration of zonisamide in epileptic patients. ( Fukuchi, H; Harada, Y; Kimura, M; Kimura, Y; Kitaura, T; Miyake, K; Tanaka, N, 1992) |
| "Zonisamide was tried on 44 children, 18 girls and 26 boys, from 8 months to 15 years of age at the start of the trial." | 1.28 | Monotherapy for childhood epilepsies with zonisamide. ( Hara, M; Hashimoto, R; Hirai, K; Kimiya, S; Kumagai, N; Seki, T; Suzuki, N; Takuma, Y; Yamada, T; Yamawaki, H, 1991) |
| "Zonisamide was found to reduce the behavioral severity of seizure responses to photic stimulation in a dose-related manner." | 1.28 | Effect of a novel anticonvulsant, zonisamide (AD-810, CI-912), in an experimental model of photosensitive epilepsy. ( Hasegawa, H; Wada, Y; Yamaguchi, N, 1990) |
| " Plasma and whole blood concentrations were measured by a high-performance liquid chromatograph method after a single dose and up to and at steady state with one or two dosage regimens." | 1.27 | Nonlinear pharmacokinetics of CI-912 in adult epileptic patients. ( Berent, S; Donofrio, PD; Sackellares, JC; Sakmar, E; Wagner, JG, 1984) |
| "Zonisamide (CI-912) is an experimental antiepileptic drug." | 1.27 | Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy. ( Buchanan, RA; Friel, PN; Levy, RH; McLean, JR; Ojemann, LM; Shastri, RA; Wilensky, AJ, 1986) |
| "Since epilepsy is a long-standing condition lasting for years to decades, short-spanned cross-sectional observations are often misleading." | 1.26 | Therapeutic concentration of antiepileptic drugs and the severity of epileptogenesis. ( Kakegawa, N; Seino, M, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (2.82) | 18.7374 |
| 1990's | 30 (14.08) | 18.2507 |
| 2000's | 94 (44.13) | 29.6817 |
| 2010's | 61 (28.64) | 24.3611 |
| 2020's | 22 (10.33) | 2.80 |
| Authors | Studies |
|---|---|
| Anger, T | 1 |
| Madge, DJ | 1 |
| Mulla, M | 1 |
| Riddall, D | 1 |
| Hen, N | 1 |
| Bialer, M | 1 |
| Yagen, B | 1 |
| Maresca, A | 1 |
| Aggarwal, M | 1 |
| Robbins, AH | 1 |
| McKenna, R | 1 |
| Scozzafava, A | 1 |
| Supuran, CT | 3 |
| Tanaka, T | 3 |
| Yajima, N | 3 |
| Tanitame, A | 1 |
| Kiyoshi, T | 3 |
| Miura, Y | 4 |
| Iwama, S | 2 |
| Mishra, CB | 1 |
| Kumari, S | 1 |
| Angeli, A | 1 |
| Bua, S | 1 |
| Mongre, RK | 1 |
| Tiwari, M | 1 |
| Marson, AG | 7 |
| Burnside, G | 2 |
| Appleton, R | 2 |
| Smith, D | 2 |
| Leach, JP | 2 |
| Sills, G | 3 |
| Tudur-Smith, C | 2 |
| Plumpton, CO | 1 |
| Hughes, DA | 2 |
| Williamson, PR | 2 |
| Baker, G | 2 |
| Balabanova, S | 2 |
| Taylor, C | 2 |
| Brown, R | 1 |
| Hindley, D | 1 |
| Howell, S | 1 |
| Maguire, M | 1 |
| Mohanraj, R | 1 |
| Smith, PE | 1 |
| Aslan, M | 1 |
| Gungor, S | 1 |
| Pennell, PB | 2 |
| Karanam, A | 1 |
| Meador, KJ | 2 |
| Gerard, E | 1 |
| Kalayjian, L | 1 |
| Penovich, P | 1 |
| Matthews, A | 1 |
| McElrath, TM | 1 |
| Birnbaum, AK | 2 |
| Itoi, T | 1 |
| Akashi, N | 1 |
| Shimizu, Y | 1 |
| Sugimoto, K | 1 |
| Hata, A | 1 |
| Kutara, K | 1 |
| Miyama, TS | 1 |
| Kanda, T | 1 |
| Revdal, E | 1 |
| Morken, G | 1 |
| Bakken, IJ | 1 |
| Bråthen, G | 1 |
| Landmark, CJ | 1 |
| Brodtkorb, E | 2 |
| Tomson, T | 2 |
| Battino, D | 1 |
| Bromley, R | 2 |
| Kochen, S | 1 |
| Thomas, SV | 1 |
| Gristina, BR | 1 |
| Waldron, RJ | 1 |
| Nettifee, JA | 2 |
| Muñana, KR | 3 |
| Willems, LM | 1 |
| van der Goten, M | 1 |
| von Podewils, F | 1 |
| Knake, S | 1 |
| Kovac, S | 1 |
| Zöllner, JP | 1 |
| Rosenow, F | 1 |
| Strzelczyk, A | 1 |
| Yoshida, S | 1 |
| Maeda, S | 1 |
| Yonezawa, T | 1 |
| Motegi, T | 1 |
| Nakatsuka, K | 1 |
| Zanghi, B | 1 |
| Hasegawa, D | 2 |
| Winter, Y | 1 |
| Sandner, K | 1 |
| Vieth, T | 1 |
| Gonzalez-Escamilla, G | 1 |
| Stuckrad-Barre, SV | 1 |
| Groppa, S | 1 |
| Quon, RJ | 1 |
| Mazanec, MT | 1 |
| Schmidt, SS | 1 |
| Andrew, AS | 1 |
| Roth, RM | 1 |
| MacKenzie, TA | 1 |
| Sajatovic, M | 1 |
| Spruill, T | 1 |
| Jobst, BC | 1 |
| Fox, J | 1 |
| Ajinkya, S | 1 |
| Lekoubou, A | 1 |
| Zhao, F | 1 |
| Liu, Y | 1 |
| Dong, H | 1 |
| Feng, S | 1 |
| Shi, G | 1 |
| Lin, L | 1 |
| Tian, Y | 1 |
| Rudakova, IG | 2 |
| Belova, YA | 2 |
| Kotov, AS | 1 |
| Romanova, MV | 1 |
| Meschede, C | 1 |
| Witt, JA | 1 |
| Brömling, S | 1 |
| Moskau-Hartmann, S | 1 |
| Rademacher, M | 1 |
| Surges, R | 1 |
| von Wrede, R | 1 |
| Helmstaedter, C | 1 |
| Ilieva, HS | 1 |
| Newman, JW | 1 |
| Fields, RK | 1 |
| Croom, JE | 1 |
| Plumpton, C | 1 |
| Smith, PEM | 1 |
| Johnson, M | 1 |
| Pirmohamed, M | 2 |
| Koo, DL | 1 |
| Nam, H | 1 |
| Casas-Alba, D | 1 |
| López-Sala, L | 1 |
| Pérez-Ordóñez, M | 1 |
| Mari-Vico, R | 1 |
| Bolasell, M | 1 |
| Martínez-Monseny, AF | 1 |
| Muchart, J | 1 |
| Fernández-Fernández, JM | 1 |
| Martorell, L | 1 |
| Serrano, M | 1 |
| Kaltseis, K | 1 |
| Frank, F | 1 |
| Broessner, G | 1 |
| McCluskey, G | 1 |
| Kinney, MO | 1 |
| Russell, A | 1 |
| Smithson, WH | 1 |
| Parsons, L | 1 |
| Morrison, PJ | 1 |
| MacKillop, L | 1 |
| Heath, C | 1 |
| Liggan, B | 1 |
| Murphy, S | 1 |
| Delanty, N | 1 |
| Irwin, B | 1 |
| Campbell, E | 1 |
| Morrow, J | 1 |
| Hunt, SJ | 1 |
| Craig, JJ | 1 |
| Nevitt, SJ | 2 |
| Sudell, M | 2 |
| Weston, J | 2 |
| Tudur Smith, C | 2 |
| Ibrahim, FA | 1 |
| El-Yazbi, AF | 1 |
| Wagih, MM | 1 |
| Barary, MA | 1 |
| Ukai, M | 1 |
| Hamamoto, Y | 1 |
| Yu, Y | 1 |
| Fujiwara-Igarashi, A | 1 |
| Fujita, M | 1 |
| Collinet, A | 1 |
| Sammut, V | 1 |
| Kumar, B | 1 |
| Medhi, B | 1 |
| Modi, M | 1 |
| Saikia, B | 1 |
| Attri, SV | 1 |
| Patial, A | 1 |
| Juhos, V | 1 |
| Reimers, A | 1 |
| Helde, G | 1 |
| Becser Andersen, N | 1 |
| Aurlien, D | 1 |
| Surlien Navjord, E | 1 |
| Haggag, K | 1 |
| Christensen, J | 1 |
| Lillestølen, KM | 1 |
| Nakken, KO | 3 |
| Adachi, R | 1 |
| Kono, M | 1 |
| Takeichi, T | 1 |
| Muro, Y | 1 |
| Akiyama, M | 1 |
| Xiao, X | 1 |
| Ouyang, Y | 1 |
| Song, Z | 1 |
| Zheng, W | 1 |
| Otamendi, AJ | 1 |
| Papich, MG | 1 |
| Park, KM | 1 |
| Lee, BI | 2 |
| Shin, KJ | 1 |
| Ha, SY | 1 |
| Park, J | 1 |
| Kim, SE | 2 |
| Laghari, AA | 1 |
| Ahmed, SI | 1 |
| Qadeer, N | 1 |
| Shamim, MS | 1 |
| Liao, YF | 1 |
| Liao, CH | 1 |
| Chu, YJ | 1 |
| Fan, PC | 1 |
| Ihara, Y | 1 |
| Hirano, A | 1 |
| Endo, S | 1 |
| Kobayashi, H | 1 |
| Torisu, T | 1 |
| Yamamoto, Y | 1 |
| Takahashi, Y | 1 |
| Imai, K | 2 |
| Mishima, N | 1 |
| Yazawa, R | 1 |
| Inoue, K | 1 |
| Itoh, K | 1 |
| Kagawa, Y | 1 |
| Inoue, Y | 2 |
| Sætre, E | 1 |
| Markhus, R | 1 |
| Lossius, MI | 1 |
| Villanueva, V | 1 |
| Serrano-Castro, PJ | 1 |
| Verrotti, A | 2 |
| Loiacono, G | 1 |
| Di Sabatino, F | 1 |
| Zaccara, G | 2 |
| Trinka, E | 1 |
| Giorgi, L | 3 |
| Patten, A | 2 |
| Segieth, J | 1 |
| Dupont, S | 1 |
| Biraben, A | 1 |
| Lavernhe, G | 1 |
| Marquet, T | 1 |
| Allaf, B | 1 |
| Ando, H | 1 |
| Matsubara, S | 1 |
| Oi, A | 1 |
| Usui, R | 1 |
| Suzuki, M | 2 |
| Fujimura, A | 1 |
| Cavanna, AE | 1 |
| Seri, S | 1 |
| Matar, KM | 1 |
| Cross, JH | 1 |
| Auvin, S | 1 |
| Wallander, KM | 1 |
| Ohman, I | 1 |
| Dahlin, M | 1 |
| Lindstrøm, P | 1 |
| Andersen, H | 1 |
| Romigi, A | 1 |
| Femia, EA | 1 |
| Fattore, C | 1 |
| Vitrani, G | 1 |
| Di Gennaro, G | 1 |
| Franco, V | 1 |
| Ackermann, AL | 1 |
| Frank, LA | 1 |
| McEntee, MF | 1 |
| May, ER | 1 |
| Kwan, SY | 1 |
| Chuang, YC | 1 |
| Huang, CW | 1 |
| Chen, TC | 1 |
| Jou, SB | 1 |
| Dash, A | 1 |
| Jongeling, AC | 1 |
| Richins, RJ | 1 |
| Bazil, CW | 1 |
| Coelho, R | 1 |
| Rodrigues, S | 1 |
| Gaspar, R | 1 |
| Silva, R | 1 |
| Lopes, J | 1 |
| Macedo, G | 1 |
| Hamer, H | 1 |
| Baulac, M | 1 |
| McMurray, R | 1 |
| Kockelmann, E | 1 |
| Takeuchi, T | 1 |
| Natsume, J | 1 |
| Kidokoro, H | 1 |
| Ishihara, N | 2 |
| Yamamoto, H | 1 |
| Azuma, Y | 1 |
| Ito, Y | 1 |
| Kurahashi, N | 1 |
| Tsuji, T | 1 |
| Itomi, K | 1 |
| Yamada, K | 1 |
| Kurahashi, H | 1 |
| Abe, S | 1 |
| Okumura, A | 2 |
| Maruyama, K | 1 |
| Negoro, T | 1 |
| Watanabe, K | 3 |
| Kojima, S | 1 |
| Farooq, MU | 1 |
| Moore, PW | 1 |
| Bhatt, A | 1 |
| Aburashed, R | 1 |
| Kassab, MY | 1 |
| Wellmer, J | 1 |
| Wellmer, S | 1 |
| Bauer, J | 2 |
| Coppola, G | 1 |
| Grosso, S | 1 |
| Parisi, P | 1 |
| Luchetti, A | 1 |
| Franzoni, E | 1 |
| Mangano, S | 1 |
| Pelliccia, A | 1 |
| Operto, FF | 1 |
| Iannetti, P | 1 |
| Curatolo, P | 1 |
| Balestri, P | 1 |
| Pascotto, A | 1 |
| Rouvel-Tallec, A | 1 |
| Valencia, I | 1 |
| Legido, A | 1 |
| Lee, YJ | 1 |
| Kang, HC | 3 |
| Seo, JH | 1 |
| Lee, JS | 2 |
| Kim, HD | 3 |
| Pellock, JM | 3 |
| Maschio, M | 2 |
| Saveriano, F | 2 |
| Dinapoli, L | 2 |
| Jandolo, B | 2 |
| Yang, LP | 1 |
| Perry, CM | 1 |
| Pompili, A | 1 |
| Carapella, CM | 1 |
| Vidiri, A | 1 |
| Tan, HJ | 1 |
| Martland, TR | 1 |
| Appleton, RE | 2 |
| Kneen, R | 1 |
| Schulze-Bonhage, A | 1 |
| Contin, M | 1 |
| Mohamed, S | 1 |
| Candela, C | 1 |
| Albani, F | 1 |
| Riva, R | 1 |
| Baruzzi, A | 1 |
| Janszky, J | 1 |
| Calabrò, RS | 1 |
| Italiano, D | 1 |
| Bramanti, P | 1 |
| Ferlazzo, E | 1 |
| Fujita, Y | 1 |
| Hasegawa, M | 3 |
| Nabeshima, K | 1 |
| Tomita, M | 1 |
| Murakami, K | 1 |
| Nakai, S | 1 |
| Yamakita, T | 1 |
| Matsunaga, K | 1 |
| Stephen, LJ | 1 |
| Kelly, K | 1 |
| Wilson, EA | 1 |
| Parker, P | 1 |
| Brodie, MJ | 4 |
| Paul, E | 1 |
| Conant, KD | 1 |
| Dunne, IE | 1 |
| Pfeifer, HH | 1 |
| Lyczkowski, DA | 1 |
| Linshaw, MA | 1 |
| Thiele, EA | 1 |
| White, JR | 1 |
| Walczak, TS | 1 |
| Marino, SE | 1 |
| Beniak, TE | 1 |
| Leppik, IE | 6 |
| Mirza, NS | 1 |
| Alfirevic, A | 1 |
| Jorgensen, A | 1 |
| Eun, SH | 1 |
| Eun, BL | 1 |
| Lee, IK | 1 |
| Chung, HJ | 1 |
| Kim, JS | 1 |
| Lee, YM | 1 |
| Suh, ES | 1 |
| Kim, DW | 2 |
| Eom, S | 1 |
| Moon, HK | 1 |
| Catarino, CB | 1 |
| Bartolini, E | 1 |
| Bell, GS | 1 |
| Yuen, AW | 1 |
| Duncan, JS | 1 |
| Sander, JW | 2 |
| Tramacere, L | 1 |
| Cincotta, M | 1 |
| Schwartz, M | 1 |
| Olby, NJ | 1 |
| Holder, JL | 1 |
| Wilfong, AA | 2 |
| Yoo, MW | 1 |
| Park, KS | 1 |
| Mil'chakova, LE | 1 |
| Gekht, AB | 1 |
| Chung, JY | 1 |
| Hwang, CY | 1 |
| Chae, JS | 1 |
| Ahn, JO | 1 |
| Kim, TH | 1 |
| Seo, KW | 1 |
| Lee, SY | 1 |
| Youn, HY | 1 |
| Ben-Menachem, E | 1 |
| Chouette, I | 1 |
| Terada, K | 1 |
| Saito, Y | 1 |
| Yanagaki, S | 1 |
| Oguni, H | 1 |
| Hayashi, K | 1 |
| Katsumori, H | 1 |
| Nagafuchi, H | 1 |
| Jo, K | 1 |
| Osawa, M | 1 |
| Kurokawa, T | 1 |
| Sirven, JI | 1 |
| Chen, JT | 1 |
| Garcia, PA | 1 |
| Alldredge, BK | 1 |
| Bergin, AM | 1 |
| Connolly, M | 1 |
| Hirose, M | 1 |
| Yokoyama, H | 1 |
| Haginoya, K | 2 |
| Iinuma, K | 4 |
| Perucca, E | 2 |
| Johannessen, SI | 2 |
| Ueda, Y | 1 |
| Doi, T | 2 |
| Tokumaru, J | 1 |
| Willmore, LJ | 5 |
| Go, T | 1 |
| Fukuoka, N | 2 |
| Tsukamoto, T | 2 |
| Uno, J | 2 |
| Kimura, M | 3 |
| Morita, S | 2 |
| Ozawa, K | 1 |
| Kobayashi, K | 1 |
| Noda, S | 1 |
| Iyo, M | 1 |
| Fujiwara, T | 1 |
| Newmark, ME | 1 |
| Dubinsky, S | 1 |
| Hasegawa, H | 3 |
| Uthman, BM | 1 |
| Miller, GS | 1 |
| Montouris, G | 1 |
| James, SP | 1 |
| Anthony, S | 1 |
| Conry, JA | 2 |
| Levy, RH | 5 |
| Ragueneau-Majlessi, I | 4 |
| Garnett, WR | 1 |
| Schmerler, M | 1 |
| Rosenfeld, W | 2 |
| Shah, J | 4 |
| Pan, WJ | 2 |
| Yagi, K | 2 |
| Seino, M | 5 |
| Miura, H | 3 |
| Seki, T | 3 |
| Kumagai, N | 3 |
| Maezawa, M | 1 |
| Yamauchi, T | 1 |
| Aikawa, H | 1 |
| Ohtahara, S | 3 |
| Yamatogi, Y | 2 |
| Bergen, D | 1 |
| Garnett, W | 1 |
| Mather, G | 1 |
| Grundy, JS | 2 |
| Smith, DF | 1 |
| Kim, HL | 1 |
| Aldridge, J | 1 |
| Rho, JM | 1 |
| Biton, V | 1 |
| Brodie, M | 2 |
| Zareba, G | 1 |
| Tosches, WA | 1 |
| Tisdell, J | 1 |
| Yoshida, T | 1 |
| Motohashi, S | 1 |
| Hamano, S | 1 |
| Sato, M | 1 |
| Borowicz, KK | 1 |
| Luszczki, JJ | 1 |
| Sobieszek, G | 1 |
| Ratnaraj, N | 1 |
| Patsalos, PN | 2 |
| Czuczwar, SJ | 1 |
| Arzimanoglou, A | 1 |
| Rahbani, A | 1 |
| Stefan, H | 1 |
| Feuerstein, TJ | 1 |
| Fukushima, K | 1 |
| Kanemoto, N | 1 |
| Kanemoto, K | 1 |
| Kamoda, T | 1 |
| Arinami, T | 1 |
| Nikaido, K | 1 |
| Kato, T | 2 |
| Takayama, R | 1 |
| Goto, S | 1 |
| Seo, T | 1 |
| Murata, T | 1 |
| Nakada, N | 1 |
| Ueda, N | 1 |
| Ishitsu, T | 1 |
| Nakagawa, K | 1 |
| Matsuura, M | 1 |
| von Klopmann, T | 1 |
| Rambeck, B | 1 |
| Tipold, A | 1 |
| Michael, CT | 1 |
| Starr, JL | 1 |
| Davenport, RD | 1 |
| Patel, NC | 1 |
| Wroe, S | 1 |
| Thöne, J | 2 |
| Wiemann, M | 2 |
| Bös, M | 1 |
| Azuma, H | 1 |
| Negi, A | 1 |
| Hattori, M | 1 |
| Masayasu, T | 1 |
| Akechi, T | 1 |
| Furukawa, TA | 1 |
| Park, SP | 1 |
| Hwang, YH | 1 |
| Lee, HW | 1 |
| Suh, CK | 1 |
| Kwon, SH | 1 |
| You, SJ | 1 |
| Lee, HS | 1 |
| Ko, TS | 1 |
| Macleod, S | 1 |
| Shinnar, S | 1 |
| Leniger, T | 1 |
| Splettstösser, F | 1 |
| Kothare, SV | 1 |
| Kaleyias, J | 1 |
| Wagner, JG | 1 |
| Sackellares, JC | 2 |
| Donofrio, PD | 1 |
| Berent, S | 1 |
| Sakmar, E | 1 |
| Kakegawa, N | 1 |
| Ito, T | 3 |
| Hori, M | 1 |
| Masuda, Y | 2 |
| Yoshida, K | 1 |
| Shimizu, M | 2 |
| Peters, DH | 1 |
| Sorkin, EM | 1 |
| Pimentel, J | 1 |
| Pinto, F | 1 |
| Hashimoto, Y | 1 |
| Odani, A | 1 |
| Tanigawara, Y | 1 |
| Yasuhara, M | 1 |
| Okuno, T | 1 |
| Hori, R | 1 |
| Yamada, T | 2 |
| Takuma, Y | 2 |
| Hirai, K | 2 |
| Shields, WD | 1 |
| Homan, RW | 1 |
| Fromm, G | 1 |
| Oommen, KJ | 1 |
| Penry, JK | 1 |
| Smith, DB | 1 |
| Lesser, RP | 1 |
| Wallace, JD | 1 |
| Kito, M | 1 |
| Maehara, M | 1 |
| Uno, H | 1 |
| Kurokawa, M | 1 |
| Shinoda, M | 1 |
| Akita, M | 1 |
| Hasegawa, T | 1 |
| Nabeshima, T | 1 |
| Kadir, ZA | 2 |
| Chadwick, DW | 3 |
| Marson, T | 1 |
| Kadir, Z | 1 |
| Kondo, T | 1 |
| Kaneko, S | 1 |
| Amano, Y | 1 |
| Egawa, I | 1 |
| Grippo, J | 1 |
| Kishi, T | 1 |
| Fujita, N | 1 |
| Eguchi, T | 1 |
| Ueda, K | 1 |
| Maeoka, Y | 1 |
| Hara, T | 1 |
| Dejima, S | 1 |
| Takeshita, K | 1 |
| Shimizu, T | 2 |
| Yamashita, Y | 1 |
| Satoi, M | 1 |
| Togo, A | 1 |
| Wada, N | 1 |
| Matsuishi, T | 1 |
| Ohnishi, A | 1 |
| Kato, H | 1 |
| Hutton, JL | 1 |
| Minami, T | 1 |
| Cho, K | 1 |
| Kajii, N | 1 |
| Tachi, N | 1 |
| Miyamoto, T | 1 |
| Kohsaka, M | 1 |
| Koyama, T | 1 |
| Vajda, FJ | 1 |
| Hayakawa, F | 1 |
| Kuno, K | 1 |
| Komatsu, M | 1 |
| Hiramatsu, M | 1 |
| Nagatomo, I | 3 |
| Akasaki, Y | 3 |
| Uchida, M | 3 |
| Tominaga, M | 3 |
| Hashiguchi, W | 3 |
| Takigawa, M | 3 |
| Jain, KK | 1 |
| McAuley, JW | 1 |
| Biederman, TS | 1 |
| Smith, JC | 1 |
| Moore, JL | 1 |
| Hakui, T | 1 |
| Fujioka, T | 1 |
| Hanada, K | 1 |
| Seike, E | 1 |
| Tounou, S | 1 |
| Sitaya, M | 1 |
| Mine, M | 1 |
| Kondou, T | 1 |
| Kawada, K | 1 |
| Itoh, S | 1 |
| Kusaka, T | 1 |
| Isobe, K | 1 |
| Ishii, M | 1 |
| Wheless, JW | 1 |
| Glauser, TA | 1 |
| Amano, S | 1 |
| Torii, R | 1 |
| Ihara, N | 1 |
| Tanaka, N | 1 |
| Kimura, Y | 1 |
| Miyake, K | 1 |
| Kitaura, T | 1 |
| Fukuchi, H | 1 |
| Harada, Y | 1 |
| Yamawaki, H | 1 |
| Suzuki, N | 1 |
| Kimiya, S | 1 |
| Hara, M | 1 |
| Hashimoto, R | 1 |
| Miyazaki, H | 1 |
| Fujimoto, Y | 1 |
| Ikoma, R | 1 |
| Shimizu, A | 2 |
| Wada, Y | 2 |
| Yamaguchi, N | 2 |
| Okuda, H | 1 |
| Yamamoto, J | 1 |
| Yamada, Y | 1 |
| Tanaka, M | 1 |
| Kawasaki, T | 1 |
| Hammond, EJ | 1 |
| Perchalski, RJ | 1 |
| Wilder, BJ | 1 |
| McLean, JR | 2 |
| Ojemann, LM | 1 |
| Shastri, RA | 1 |
| Wilensky, AJ | 1 |
| Friel, PN | 1 |
| Buchanan, RA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Physiological-based Pharmacokinetics Approach to Determine the Extent of Drug Exposure of Antiseizure Medications During Pregnancy and Breastfeeding[NCT05450978] | 60 participants (Anticipated) | Observational [Patient Registry] | 2022-07-20 | Recruiting | |||
| Clinical Cohort Study of Association Between Steady State Phenytoin Treatment and Better Clinical Parameters of Glaucoma[NCT00739154] | 200 participants (Anticipated) | Observational | 2008-11-30 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
59 reviews available for zonisamide and Aura
| Article | Year |
|---|---|
Medicinal chemistry of neuronal voltage-gated sodium channel blockers.
Topics: Amyotrophic Lateral Sclerosis; Analgesics; Anticonvulsants; Epilepsy; Humans; Ion Channel Gating; Mo | 2001 |
Breastfeeding while on treatment with antiseizure medications: a systematic review from the ILAE Women Task Force
Topics: Breast Feeding; Cannabidiol; Carbamazepine; Child; Clobazam; Clonazepam; Epilepsy; Ethosuximide; Eve | 2022 |
Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.
Topics: Adult; Amines; Anticonvulsants; Carbamazepine; Child; Cyclohexanecarboxylic Acids; Epilepsies, Parti | 2017 |
Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.
Topics: Adult; Amines; Anticonvulsants; Carbamazepine; Child; Cyclohexanecarboxylic Acids; Epilepsies, Parti | 2017 |
[The role of zonisamide in the treatment of women with epilepsy].
Topics: Anticonvulsants; Epilepsy; Female; Humans; Isoxazoles; Zonisamide | 2016 |
Choice of therapeutic anti-seizure medication in patients with brain tumour.
Topics: Anticonvulsants; Brain Neoplasms; Drug Therapy, Combination; Epilepsy; Gabapentin; Glioma; Humans; L | 2019 |
[Epilepsy in the elderly].
Topics: Age Factors; Aged; Aging; Anticonvulsants; Dose-Response Relationship, Drug; Epilepsy; Humans; Isoxa | 2013 |
[Zonisamide in the epilepsy treatment: a literature review from add-on therapy to monotherapy].
Topics: Adult; Animals; Anorexia; Anticonvulsants; Antioxidants; Carbonic Anhydrase Inhibitors; Child; Dizzi | 2013 |
The adverse event profile of zonisamide: a meta-analysis.
Topics: Anticonvulsants; Clinical Trials as Topic; Databases, Factual; Epilepsy; Humans; Isoxazoles; Zonisam | 2013 |
Zonisamide in the management of epilepsy in the elderly.
Topics: Aged; Anticonvulsants; Drug Therapy, Combination; Epilepsy; Humans; Isoxazoles; Zonisamide | 2015 |
[New possibilities of monotherapy of symptomatic and cryptogenic partial epilepsy].
Topics: Anticonvulsants; Carbamazepine; Epilepsies, Partial; Epilepsy; Humans; Isoxazoles; Zonisamide | 2015 |
Therapeutic role of zonisamide in neuropsychiatric disorders.
Topics: Adult; Animals; Anticonvulsants; Child; Clinical Trials as Topic; Epilepsy; Humans; Isoxazoles; Psyc | 2008 |
[Role of monotherapy with new antiepileptic drugs in the treatment of childhood epilepsy].
Topics: Anticonvulsants; Carbamazepine; Child; Drug Administration Schedule; Epilepsy; Fructose; Humans; Iso | 2009 |
New pharmacotherapies for pediatric seizures.
Topics: Adolescent; Amines; Animals; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Cyclohexanecar | 2004 |
Zonisamide in the treatment of epilepsy.
Topics: Adult; Animals; Anticonvulsants; Clinical Trials as Topic; Compassionate Use Trials; Disease Models, | 2010 |
[Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases].
Topics: Anticonvulsants; Bipolar Disorder; Calcium Channels, T-Type; Cholinergic Agents; Dopamine Agents; Dy | 2009 |
Drug safety evaluation of zonisamide for the treatment of epilepsy.
Topics: Animals; Drug-Related Side Effects and Adverse Reactions; Epilepsy; Humans; Isoxazoles; Kidney Calcu | 2011 |
Zonisamide in the treatment of epilepsy.
Topics: Animals; Anticonvulsants; Calcium Channel Blockers; Calcium Channels, T-Type; Epilepsy; Humans; Isox | 2011 |
[New drugs in the treatment of adult patients with refractery epilepsy].
Topics: Adult; Anticonvulsants; Dibenzazepines; Epilepsy; Humans; Isoxazoles; Zonisamide | 2011 |
Zonisamide: its pharmacology, efficacy and safety in clinical trials.
Topics: Animals; Anticonvulsants; Clinical Trials as Topic; Dose-Response Relationship, Drug; Epilepsy; Huma | 2012 |
Antiepileptic drug therapy for adults: when to initiate and how to choose.
Topics: Acetates; Adult; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Epilepsy; Felb | 2002 |
New antiepileptic drug therapies.
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Child; Cyclohexanecarboxylic Acids; Dioxolanes; Ep | 2002 |
The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come?
Topics: Acetates; Amines; Animals; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Interac | 2003 |
[Clinical guidelines for treatment of epilepsy in children].
Topics: Anticonvulsants; Benzodiazepines; Carbamazepine; Child; Cosyntropin; Electroencephalography; Epileps | 2004 |
Pharmacologic treatment of the catastrophic epilepsies.
Topics: Anticonvulsants; Child, Preschool; Epilepsies, Myoclonic; Epilepsy; Fructose; Humans; Infant; Isoxaz | 2004 |
Review of zonisamide development in Japan.
Topics: Animals; Anticonvulsants; Clinical Trials as Topic; Epilepsy; Humans; Isoxazoles; Japan; Product Sur | 2004 |
Zonisamide overview of the United States experience.
Topics: Anticonvulsants; Epilepsy; Humans; Isoxazoles; Retrospective Studies; United States; Zonisamide | 2004 |
Zonisamide: newer antiepileptic agent with multiple mechanisms of action.
Topics: Animals; Anticonvulsants; Dose-Response Relationship, Drug; Drug Interactions; Drug Tolerance; Epile | 2004 |
Antiepileptic drugs and neuroprotection: current status and future roles.
Topics: Animals; Anticonvulsants; Brain; Epilepsy; Fructose; Humans; Isoxazoles; Lamotrigine; Levetiracetam; | 2005 |
Zonisamide in the management of epilepsy--Japanese experience.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Clinical Trials as Topic; Drug Therapy, | 2006 |
Zonisamide: review of its use in epilepsy therapy.
Topics: Animals; Anticonvulsants; Biological Availability; Child; Child, Preschool; Drug Interactions; Epile | 2005 |
Practical prescribing and long-term efficacy and safety of zonisamide.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Child, Preschool; Clinical Trials as Topic; Epileps | 2006 |
Zonisamide for the treatment of epilepsy.
Topics: Anticonvulsants; Clinical Trials as Topic; Epilepsy; Humans; Isoxazoles; Practice Patterns, Physicia | 2006 |
Novel anticonvulsant drugs.
Topics: Amines; Animals; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Epilepsy; Fructose; Ga | 2007 |
Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?
Topics: Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Interactions; Drug Monitor | 2006 |
[Newer antiepileptic drugs].
Topics: Amines; Animals; Anti-Anxiety Agents; Anticonvulsants; Calcium Channel Blockers; Carbamazepine; Cycl | 2007 |
Pharmacokinetics and drug interactions with zonisamide.
Topics: Anticonvulsants; Contraceptives, Oral; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug | 2007 |
The new antiepileptic drugs.
Topics: Amines; Anticonvulsants; Carbamazepine; Child; Cyclohexanecarboxylic Acids; Dioxolanes; Epilepsies, | 2007 |
Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety.
Topics: Analgesics, Non-Narcotic; Anticonvulsants; Brain Diseases; Clinical Trials as Topic; Epilepsy; Human | 2008 |
Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy.
Topics: Animals; Anticonvulsants; Clinical Trials as Topic; Epilepsy; Humans; Isoxazoles; Zonisamide | 1993 |
[New antiepileptic medications].
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Epilepsy; Gabapentin; | 1995 |
Newer antiepileptic drugs. Towards an improved risk-benefit ratio.
Topics: Acetamides; Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Dioxolane | 1994 |
Antiepileptic drugs in development: prospects for the near future.
Topics: Acetates; Adult; Amines; Aminocaproates; Animals; Anticonvulsants; Clinical Trials as Topic; Cyclohe | 1994 |
Investigational antiepileptic drugs for the treatment of childhood seizure disorders: a review of efficacy and safety.
Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Child; Clinical Trials as | 1994 |
[Research and development of zonisamide, a new type of antiepileptic drug].
Topics: Animals; Anticonvulsants; Clinical Trials as Topic; Dogs; Drug Design; Electroencephalography; Epile | 1996 |
New antiepileptic drugs: a systematic review of their efficacy and tolerability.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Anticonvulsants; Child; Cross-Over Studies; Cyclohexaneca | 1996 |
Clinical administration of new antiepileptic drugs: an overview of safety and efficacy.
Topics: Acetates; Amines; Anticonvulsants; Confidence Intervals; Cyclohexanecarboxylic Acids; Drug Interacti | 1996 |
[Treatment of the epilepsy: new drugs].
Topics: Acetates; Amines; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Carbamaz | 1996 |
The new antiepileptic drugs: a systematic review of their efficacy and tolerability.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Drug | 1997 |
Zonisamide.
Topics: Adult; Animals; Anticonvulsants; Clinical Trials as Topic; Disease Models, Animal; Drug Administrati | 1999 |
The clinical pharmacokinetics of the new antiepileptic drugs.
Topics: Acetates; Amines; Anticonvulsants; Biological Availability; Cyclohexanecarboxylic Acids; Dose-Respon | 1999 |
New antiepileptic drugs.
Topics: Acetates; Amines; Animals; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Interac | 2000 |
An assessment of zonisamide as an anti-epileptic drug.
Topics: Adolescent; Adult; Aged; Animals; Anticonvulsants; Child; Clinical Trials as Topic; Epilepsy; Female | 2000 |
Newer therapies in the drug treatment of epilepsy.
Topics: Anticonvulsants; Carbamazepine; Clinical Trials as Topic; Drug Interactions; Epilepsy; Humans; Isoxa | 2002 |
Three new drugs for epilepsy: levetiracetam, oxcarbazepine, and zonisamide.
Topics: Anticonvulsants; Carbamazepine; Clinical Trials as Topic; Epilepsy; Humans; Isoxazoles; Levetiraceta | 2002 |
Using the new antiepilepsy drugs in children.
Topics: Anticonvulsants; Carbamazepine; Child; Clinical Trials as Topic; Epilepsy; Humans; Isoxazoles; Levet | 2002 |
Zonisamide in pediatric epilepsy: review of the Japanese experience.
Topics: Adult; Anticonvulsants; Child; Clinical Trials as Topic; Drug Therapy, Combination; Epilepsy; Humans | 2002 |
Zonisamide.
Topics: Animals; Anticonvulsants; Brain; Drugs, Investigational; Electroencephalography; Epilepsy; Evoked Po | 1991 |
Neuropharmacology of zonisamide, a new antiepileptic drug.
Topics: Animals; Anticonvulsants; Blood-Brain Barrier; Carbonic Anhydrase Inhibitors; Drug Interactions; Epi | 1987 |
27 trials available for zonisamide and Aura
| Article | Year |
|---|---|
Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.
Topics: Child, Preschool; Cost-Benefit Analysis; Epilepsies, Partial; Epilepsy; Female; Humans; Lamotrigine; | 2021 |
Efficacy evaluation of a commercially available MCT enriched therapeutic diet on dogs with idiopathic epilepsy treated with zonisamide: a prospective, randomized, double-blinded, placebo-controlled, crossover dietary preliminary study.
Topics: Animals; Diet; Dog Diseases; Dogs; Epilepsy; Prospective Studies; Seizures; Triglycerides; Zonisamid | 2023 |
Study protocol for a pragmatic randomised controlled trial comparing the effectiveness and cost-effectiveness of levetiracetam and zonisamide versus standard treatments for epilepsy: a comparison of standard and new antiepileptic drugs (SANAD-II).
Topics: Anticonvulsants; Carbamazepine; Child; Child, Preschool; Clinical Trials as Topic; Cost-Benefit Anal | 2020 |
Zonisamide in children and young adults with refractory epilepsy: an open label, multicenter Italian study.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Drug Tolerance; Electroencephalography; | 2009 |
Efficacy and tolerability of adjunctive therapy with zonisamide in childhood intractable epilepsy.
Topics: Adolescent; Anticonvulsants; Chemotherapy, Adjuvant; Child; Child, Preschool; Dose-Response Relation | 2010 |
Comparative trial of low- and high-dose zonisamide as monotherapy for childhood epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Adminis | 2011 |
Zonisamide monotherapy for idiopathic epilepsy in dogs.
Topics: Animals; Anticonvulsants; Dog Diseases; Dogs; Epilepsy; Isoxazoles; Zonisamide | 2012 |
Zonisamide monotherapy in a multi-group clinic.
Topics: Adolescent; Adult; Aged; Ambulatory Care Facilities; Anticonvulsants; Drug Administration Schedule; | 2004 |
Safety of 25- and 50-mg capsules in the initiation of zonisamide therapy in patients with epilepsy: an uncontrolled, open-label study.
Topics: Adult; Anticonvulsants; Dose-Response Relationship, Drug; Epilepsy; Female; Humans; Isoxazoles; Male | 2004 |
Lack of a clinically significant effect of zonisamide on phenytoin steady-state pharmacokinetics in patients with epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Area Under Curve; Drug Interactions; Epilepsy; Female; Humans; I | 2004 |
Zonisamide monotherapy with once-daily dosing in children with cryptogenic localization-related epilepsies: clinical effects and pharmacokinetic studies.
Topics: Adolescent; Age Factors; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Dose-Response Rela | 2004 |
Clinical efficacy of zonisamide in childhood epilepsy after long-term treatment: a postmarketing, multi-institutional survey.
Topics: Adolescent; Age Factors; Anticonvulsants; Child; Child, Preschool; Disability Evaluation; Drug Inter | 2004 |
Effects of zonisamide monotherapy in children with epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Drug Administration Schedule; Electroencephalo | 2004 |
Efficacy of zonisamide: our experience.
Topics: Adolescent; Adult; Anticonvulsants; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epi | 2004 |
Zonisamide clinical trials: European experience.
Topics: Adult; Anticonvulsants; Demography; Double-Blind Method; Epilepsy; Europe; Female; Humans; Isoxazole | 2004 |
Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients.
Topics: Adolescent; Adult; Anticonvulsants; Area Under Curve; Biotransformation; Carbamazepine; Cytochrome P | 2004 |
Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy.
Topics: Adult; Area Under Curve; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; E | 2005 |
Prospective study of zonisamide therapy for refractory idiopathic epilepsy in dogs.
Topics: Administration, Oral; Animals; Anticonvulsants; Dog Diseases; Dogs; Epilepsy; Isoxazoles; Prospectiv | 2007 |
Zonisamide and renal calculi in patients with epilepsy: how big an issue?
Topics: Adolescent; Adult; Anticonvulsants; Child; Double-Blind Method; Epilepsy; Female; Fructose; Humans; | 2007 |
[Anticonvulsant treatment with zonisamide added to topiramate. A preliminary treatment analysis in 19 patients].
Topics: Adult; Aged; Anticonvulsants; Child; Drug Therapy, Combination; Epilepsy; Female; Fructose; Humans; | 2007 |
Long-term cognitive and mood effects of zonisamide monotherapy in epilepsy patients.
Topics: Adolescent; Adult; Affect; Anticonvulsants; Cognition; Dose-Response Relationship, Drug; Electroence | 2008 |
Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Adminis | 2009 |
Developmental and therapeutic pharmacology of antiepileptic drugs.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Dose-Response Relationship, Dru | 1993 |
Efficacy and safety of zonisamide: results of a multicenter study.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Epilepsy; Female; Humans; Isoxazoles; Male; Middle | 1993 |
Long-term effects of zonisamide in the treatment of epilepsy in children with intellectual disability.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Humans; Infant; Intellectual | 1998 |
Predictive value of acetylcholine stimulation testing for oligohidrosis caused by zonisamide.
Topics: Acetylcholine; Anticonvulsants; Child; Child, Preschool; Cholinergic Agents; Epilepsy; False Positiv | 2000 |
Developmental and therapeutic pharmacology of antiepileptic drugs.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Drug Admini | 2000 |
127 other studies available for zonisamide and Aura
| Article | Year |
|---|---|
Anticonvulsant 4-aminobenzenesulfonamide derivatives with branched-alkylamide moieties: X-ray crystallography and inhibition studies of human carbonic anhydrase isoforms I, II, VII, and XIV.
Topics: Anticonvulsants; Binding Sites; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Crystallography, | 2011 |
Discovery of benzothiazine derivatives as novel, orally-active anti-epileptic drug candidates with broad anticonvulsant effect.
Topics: Administration, Oral; Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, | 2015 |
Simple N,N-dimethyl phenylsulfonamides show potent anticonvulsant effect in two standard epilepsy models.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Electroshock; Ep | 2017 |
N-alkyl-[1,1'-biphenyl]-2-sulfonamide derivatives as novel broad spectrum anti-epileptic drugs with efficacy equivalent to that of sodium valproate.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Epilepsy; Mice; | 2017 |
Discovery of Potent Carbonic Anhydrase Inhibitors as Effective Anticonvulsant Agents: Drug Design, Synthesis, and In Vitro and In Vivo Investigations.
Topics: Animals; Anticonvulsants; Carbonic Anhydrase I; Carbonic Anhydrase II; Carbonic Anhydrase Inhibitors | 2021 |
Effectiveness of zonisamide in childhood refractory epilepsy.
Topics: Child; Drug Resistant Epilepsy; Epilepsies, Partial; Epilepsy; Humans; Reproducibility of Results; R | 2022 |
Antiseizure Medication Concentrations During Pregnancy: Results From the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) Study.
Topics: Adult; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Lacosamide; Lamotrigine; Levetirace | 2022 |
Distal renal tubular acidosis and lethargy associated with zonisamide treatment in a dog with idiopathic epilepsy.
Topics: Acidosis, Renal Tubular; Animals; Bicarbonates; Dog Diseases; Dogs; Epilepsy; Lethargy; Male; Zonisa | 2022 |
Bidirectionality of antiseizure and antipsychotic treatment: A population-based study.
Topics: Anticonvulsants; Antipsychotic Agents; Epilepsy; Humans; Levetiracetam; Psychotic Disorders; Zonisam | 2022 |
Comparison of caregivers' assessments of clinical outcome in dogs with idiopathic epilepsy administered levetiracetam, zonisamide, or phenobarbital monotherapy.
Topics: Animals; Anticonvulsants; Caregivers; Dog Diseases; Dogs; Epilepsy; Humans; Levetiracetam; Phenobarb | 2023 |
Adverse Event Profiles of Antiseizure Medications and the Impact of Coadministration on Drug Tolerability in Adults with Epilepsy.
Topics: Adult; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Anticonvulsants; Epilepsy; Humans; | 2023 |
Evaluation of antiseizure medications including zonisamide in feline idiopathic epilepsy at a referral hospital in Japan.
Topics: Animals; Cat Diseases; Cats; Epilepsy; Hospitals; Japan; Referral and Consultation; Retrospective St | 2023 |
Third-Generation Antiseizure Medication in the Treatment of Benzodiazepine-Refractory Status Epilepticus in Poststroke Epilepsy: A Retrospective Observational Register-Based Study.
Topics: Aged; Anticonvulsants; Benzodiazepines; Epilepsy; Humans; Ischemic Stroke; Lacosamide; Middle Aged; | 2023 |
Antiepileptic drug effects on subjective and objective cognition.
Topics: Adult; Anticonvulsants; Cognition; Cognitive Dysfunction; Diagnostic Self Evaluation; Epilepsy; Fema | 2020 |
Patterns of antiepileptic drug use among elderly patients with epilepsy: 2004-2015.
Topics: Aged; Aged, 80 and over; Aging; Anticonvulsants; Carbamazepine; Cross-Sectional Studies; Epilepsy; F | 2020 |
An Electrochemophysiological Microarray for Real-Time Monitoring and Quantification of Multiple Ions in the Brain of a Freely Moving Rat.
Topics: Animals; Anticonvulsants; Brain; Calcium; Carbamates; Diamines; Electrochemical Techniques; Epilepsy | 2020 |
[A retrospective analysis of using zonisamide and retention in monotherapy among patients with epilepsy in routine clinical practice].
Topics: Adolescent; Adult; Aged; Anticonvulsants; Epilepsy; Humans; Middle Aged; Retrospective Studies; Russ | 2019 |
Changes in cognition after introduction or withdrawal of zonisamide versus topiramate in epilepsy patients: A retrospective study using Bayes statistics.
Topics: Adolescent; Adult; Anticonvulsants; Bayes Theorem; Cognition; Epilepsy; Executive Function; Female; | 2020 |
Valproic acid and zonisamide induced hyperammonemic encephalopathy.
Topics: Adult; Anticonvulsants; Brain; Brain Diseases; Epilepsy; Humans; Hyperammonemia; Magnetic Resonance | 2020 |
Effects of zonisamide monotherapy on bone health in drug-naive epileptic patients.
Topics: Absorptiometry, Photon; Adolescent; Adult; Aged; Anticonvulsants; Biomarkers; Bone Density; Epilepsy | 2020 |
Early-onset severe spinocerebellar ataxia 42 with neurodevelopmental deficits (SCA42ND): Case report, pharmacological trial, and literature review.
Topics: Age of Onset; Alleles; Calcium Channels, T-Type; Child, Preschool; Epilepsy; Female; Gain of Functio | 2021 |
Zonisamide as treatment option in persistent migraine aura.
Topics: Adolescent; Drug-Related Side Effects and Adverse Reactions; Epilepsy; Female; Humans; Migraine Diso | 2021 |
Zonisamide safety in pregnancy: Data from the UK and Ireland epilepsy and pregnancy register.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Epilepsy; Female; Follow-Up Studies; Humans; Ireland; | 2021 |
Chromatographic determination of zonisamide, topiramate and sulpiride in plasma by a fluorescent 'turn-on' chemosensor.
Topics: Adult; Anticonvulsants; Blood Chemical Analysis; Chromatography, High Pressure Liquid; Epilepsy; Fem | 2017 |
Efficacy of zonisamide on interictal electroencephalography in familial spontaneous epileptic cats.
Topics: Animals; Anticonvulsants; Cat Diseases; Cats; Electroencephalography; Epilepsy; Female; Male; Scalp; | 2018 |
Suspected zonisamide-related anticonvulsant hypersensitivity syndrome in a cat.
Topics: Animals; Anticonvulsants; Cat Diseases; Cats; Diagnosis, Differential; Drug Hypersensitivity; Epilep | 2017 |
A mechanistic approach to explore the neuroprotective potential of zonisamide in seizures.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Electroshock; Epilepsy; Free Radicals; Inflammatio | 2018 |
Zonisamide serum concentrations during pregnancy.
Topics: Adult; Denmark; Drug Monitoring; Epilepsy; Female; Gestational Age; Humans; Norway; Pregnancy; Pregn | 2018 |
Eosinophilia and systemic symptoms with transient ageusia: a drug reaction caused by zonisamide.
Topics: Ageusia; Anticonvulsants; Drug Hypersensitivity Syndrome; Epilepsy; Humans; Male; Middle Aged; Zonis | 2018 |
[Progress in synaptic mechanism in epileptogenesis].
Topics: Anticonvulsants; Carbamazepine; Epilepsy; Humans; Isoxazoles; N-Ethylmaleimide-Sensitive Proteins; N | 2018 |
Population pharmacokinetics of extended-release levetiracetam in epileptic dogs when administered alone, with phenobarbital or zonisamide.
Topics: Animals; Anticonvulsants; Delayed-Action Preparations; Dog Diseases; Dogs; Drug Interactions; Epilep | 2018 |
Efficacy, tolerability, and blood concentration of zonisamide in daily clinical practice.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Epilepsy; Female; Humans; Middle Aged; Retrospective Studi | 2019 |
Pharmacotherapy and electroencephalographic evolution in SCN8A encephalopathy: A case report.
Topics: Anticonvulsants; Brain Diseases; Diagnosis, Differential; Electroencephalography; Epilepsy; Humans; | 2019 |
Gastrointestinal: A case of zonisamide-induced esophageal and small intestinal injury.
Topics: Anticonvulsants; Duodenal Ulcer; Epilepsy; Esophageal Diseases; Glucocorticoids; Humans; Ileum; Male | 2019 |
Risk factors for hyperammonemia in pediatric patients with epilepsy.
Topics: Acetazolamide; Adolescent; Age Factors; Anticonvulsants; Child; Child, Preschool; Dose-Response Rela | 2013 |
Safety and tolerability of zonisamide in elderly patients with epilepsy.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Databases, Bibliographic; Dose-Response Relationship, Drug | 2013 |
Management and monitoring of patients treated with zonisamide: the OZONE study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Data Collection; Data Interpretation, S | 2013 |
Two nursing mothers treated with zonisamide: Should breast-feeding be avoided?
Topics: Adult; Anticonvulsants; Biological Availability; Breast Feeding; Child Development; Epilepsy; Female | 2014 |
Psychiatric adverse effects of zonisamide in patients with epilepsy and mental disorder comorbidities.
Topics: Adolescent; Adult; Anticonvulsants; Child; Comorbidity; Electroencephalography; Epilepsy; Female; Hu | 2013 |
Impact of pregnancy on zonisamide pharmacokinetics in rabbits.
Topics: Administration, Oral; Animals; Anticonvulsants; Epilepsy; Female; Humans; Isoxazoles; Pregnancy; Rab | 2013 |
Safety and tolerability of zonisamide in paediatric patients with epilepsy.
Topics: Anticonvulsants; Child; Child, Preschool; Controlled Clinical Trials as Topic; Drug Therapy, Combina | 2014 |
Zonisamide: pharmacokinetics, efficacy, and adverse events in children with epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Humans; Infant; Infant, Newb | 2014 |
Retention rate of zonisamide in intractable epilepsy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Denmark; Drug Therapy, Combination; Epilepsy; Female; Huma | 2015 |
Erythema multiforme associated with zonisamide in a dog.
Topics: Animals; Anticonvulsants; Dog Diseases; Dogs; Epilepsy; Erythema Multiforme; Isoxazoles; Male; Skin; | 2015 |
Zonisamide: Review of Recent Clinical Evidence for Treatment of Epilepsy.
Topics: Anticonvulsants; Drug Interactions; Epilepsy; Humans; Isoxazoles; Randomized Controlled Trials as To | 2015 |
Safety and tolerability of an oral zonisamide loading dose.
Topics: Administration, Oral; Adult; Aged; Anticonvulsants; Drug Administration Schedule; Epilepsy; Female; | 2015 |
Zonisamide-induced Acute-on-Chronic Liver Failure: First Report.
Topics: Acute-On-Chronic Liver Failure; Adult; Alcoholism; Anticonvulsants; Epilepsy; Female; Humans; Isoxaz | 2016 |
Retention, dosing, tolerability and patient reported seizure outcome of Zonisamide as only add-on treatment under real-life conditions in adult patients with partial onset seizures: Results of the observational study ZOOM.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Drug Therapy, Combination; Drug Toleran | 2016 |
The effects of co-medications on lamotrigine clearance in Japanese children with epilepsy.
Topics: Adolescent; Anticonvulsants; Benzodiazepines; Carbamazepine; Child; Child, Preschool; Clobazam; Clon | 2016 |
Antiepileptic activity of zonisamide on hippocampal CA3 neurons does not depend on carbonic anhydrase inhibition.
Topics: Animals; Anticonvulsants; Carbonic Anhydrase II; Carbonic Anhydrase Inhibitors; Epilepsy; Hippocampu | 2008 |
The impact of zonisamide on weight. A clinical study in 103 patients with epilepsy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Body Mass Index; Body Weight; Dose-Response Relationship, | 2009 |
[New antiepileptic drugs].
Topics: Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Epilepsies, Partial; Epilepsy; | 2009 |
Reversible erectile dysfunction in a patient with brain tumor-related epilepsy in therapy with zonisamide in add-on.
Topics: Adult; Anticonvulsants; Astrocytoma; Brain Neoplasms; Epilepsy; Erectile Dysfunction; Humans; Isoxaz | 2011 |
Zonisamide: in Parkinson's disease.
Topics: Animals; Antioxidants; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration | 2009 |
Efficacy and tolerability of zonisamide as add-on in brain tumor-related epilepsy: preliminary report.
Topics: Adult; Anticonvulsants; Brain Neoplasms; Dose-Response Relationship, Drug; Drug Therapy, Combination | 2009 |
Effectiveness and tolerability of zonisamide in children with epilepsy: a retrospective review.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Drug Evaluation; Epilepsy; Female; Humans; Inf | 2010 |
Simultaneous HPLC-UV analysis of rufinamide, zonisamide, lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in deproteinized plasma of patients with epilepsy.
Topics: Anticonvulsants; Carbamazepine; Chromatography, High Pressure Liquid; Epilepsy; Felbamate; Humans; I | 2010 |
Zonisamide-related erectile dysfunction.
Topics: Anticonvulsants; Brain Neoplasms; Epilepsy; Humans; Impotence, Vasculogenic; Isoxazoles; Male; Nitri | 2011 |
Acute kidney injury caused by zonisamide-induced hypersensitivity syndrome.
Topics: Acute Kidney Injury; Adrenal Cortex Hormones; Adult; Anticonvulsants; Drug Hypersensitivity; Epileps | 2010 |
A prospective audit of adjunctive zonisamide in an everyday clinical setting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Chemotherapy, Adjuvant; Electroencephal | 2010 |
Urolithiasis on the ketogenic diet with concurrent topiramate or zonisamide therapy.
Topics: Anticonvulsants; Child; Child, Preschool; Combined Modality Therapy; Diet, Ketogenic; Epilepsy; Fema | 2010 |
Zonisamide discontinuation due to psychiatric and cognitive adverse events: a case-control study.
Topics: Adult; Anticonvulsants; Case-Control Studies; Cognition Disorders; Epilepsy; Female; Humans; Isoxazo | 2010 |
Metabolic acidosis with topiramate and zonisamide: an assessment of its severity and predictors.
Topics: Acid-Base Equilibrium; Acidosis, Renal Tubular; Adult; Aged; Carbonic Anhydrase Inhibitors; Carbonic | 2011 |
The long-term retention of zonisamide in a large cohort of people with epilepsy at a tertiary referral centre.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Cohort Studies; Epilepsy; Female; Humans; Isoxazoles; Male | 2011 |
Possible drug-induced hepatopathy in a dog receiving zonisamide monotherapy for treatment of cryptogenic epilepsy.
Topics: Animals; Anticonvulsants; Chemical and Drug Induced Liver Injury; Dog Diseases; Dogs; Epilepsy; Fema | 2011 |
Low serum leptin level is associated with zonisamide-induced weight loss in overweight female epilepsy patients.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Epilepsy; Female; Follow-Up Studies; Humans; Isoxazoles; L | 2012 |
[Clinical application of newer anti-epileptic drugs].
Topics: Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Female; Fructose; Gabapentin; gamma- | 2012 |
[Urolithiasis induced by combined ACTH and zonisamide treatment in a patient with startle induced epilepsy].
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Child, Preschool; Drug Therapy, Combination; Epilepsy; | 2002 |
[Clinical features and treatment of refractory epilepsy in children].
Topics: Adolescent; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Clobazam | 2001 |
Zonisamide-induced restless legs syndrome.
Topics: Adult; Anticonvulsants; Dose-Response Relationship, Drug; Electroencephalography; Epilepsy; Fatigue; | 2003 |
[A five-year-old girl with epilepsy showing forced normalization due to zonisamide].
Topics: Anticonvulsants; Child Behavior Disorders; Child, Preschool; Communication Disorders; Electroencepha | 2003 |
Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures.
Topics: Amino Acid Transport System X-AG; Amygdala; Animals; Anticonvulsants; Blotting, Western; Carrier Pro | 2003 |
Effect of antiepileptic drug monotherapy on crystalluria in children and young adults.
Topics: Adolescent; Anticonvulsants; Child; Epilepsy; Female; Humans; Isoxazoles; Male; Retrospective Studie | 2003 |
Influence of coadministered antiepileptic drugs on serum zonisamide concentrations in epileptic patients: quantitative analysis based on suitable transforming factor.
Topics: Administration, Oral; Adolescent; Adult; Aging; Anticonvulsants; Biological Availability; Body Surfa | 2003 |
Zonisamide-induced depression and mania in patients with epilepsy.
Topics: Adult; Bipolar Disorder; Depression; Epilepsy; Humans; Isoxazoles; Male; Polypharmacy; Treatment Out | 2004 |
Utilization of zonisamide in patients with chronic pain or epilepsy refractory to other treatments: a retrospective, open label, uncontrolled study in a VA hospital.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Epilepsy; Humans; Isoxazoles; Male; Middl | 2004 |
Overview of Japanese experience-controlled and uncontrolled trials.
Topics: Adolescent; Age Distribution; Anticonvulsants; Child; Child, Preschool; Clinical Trials, Phase II as | 2004 |
Safety of zonisamide therapy: prospective follow-up survey.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Age Factors; Aged; Anticonvulsants; Child; Child, Pr | 2004 |
Influence of coadministered antiepileptic drugs on serum phenobarbital concentrations in epileptic patients: quantitative analysis based on a suitable transforming factor.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Child; Chil | 2004 |
Zonisamide monotherapy for epilepsy in children and young adults.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Child; Child, Preschool; Epilepsy; Humans; Infant; | 2005 |
Clinical experience with zonisamide monotherapy and adjunctive therapy in children with epilepsy at a tertiary care referral center.
Topics: Adolescent; Anticonvulsants; Chemotherapy, Adjuvant; Child; Child, Preschool; Dose-Response Relation | 2005 |
Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy.
Topics: Adult; Anticonvulsants; Drug Interactions; Epilepsy; Female; Humans; Isoxazoles; Male; Middle Aged; | 2005 |
[Effective and 15 years experience. New add-on option in epilepsy therapy]].
Topics: Anticonvulsants; Body Weight; Child; Controlled Clinical Trials as Topic; Dose-Response Relationship | 2005 |
[Control of side effects. Add on therapy demonstrates good tolerance].
Topics: Anticonvulsants; Body Weight; Controlled Clinical Trials as Topic; Drug Interactions; Drug Therapy, | 2005 |
Long-term efficacy and safety of monotherapy and adjunctive therapy with zonisamide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Drug Therapy, Combination; Epilepsy; Fe | 2006 |
Simultaneous determination of zonisamide, carbamazepine and carbamazepine-10,11-epoxide in infant serum by high-performance liquid chromatography.
Topics: Anticonvulsants; Carbamazepine; Chromatography, High Pressure Liquid; Epilepsy; Humans; Infant; Isox | 2006 |
Interactions between zonisamide and conventional antiepileptic drugs in the mouse maximal electroshock test model.
Topics: Animals; Anticonvulsants; Brain Chemistry; Chromatography, High Pressure Liquid; Disease Models, Ani | 2007 |
A long-term follow-up of zonisamide monotherapy.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Child; Epilepsy; Female; Follow-Up Studies; Humans; | 2006 |
A case of Moebius syndrome presenting with congenital bilateral vocal cord paralysis.
Topics: Anticonvulsants; Epilepsy; Female; Humans; Infant, Newborn; Isoxazoles; Mobius Syndrome; Pregnancy; | 2007 |
[Valproate sodium and zonisamide associated interstitial pneumonitis in an infant].
Topics: Anticonvulsants; Epilepsy; Female; Humans; Infant; Isoxazoles; Lung Diseases, Interstitial; Respirat | 2007 |
Erratum to "Safety of zonisamide therapy: prospective follow-up survey.".
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Age Factors; Aged; Anticonvulsants; Child; Child, Pr | 2007 |
Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese.
Topics: Adult; Algorithms; Anticonvulsants; Aryl Hydrocarbon Hydroxylases; Asian People; Cytochrome P-450 CY | 2007 |
Psychosis following initiation of zonisamide.
Topics: Anticonvulsants; Epilepsy; Female; Humans; Isoxazoles; Middle Aged; Psychoses, Substance-Induced; Zo | 2007 |
Zonisamide as treatment for seizures.
Topics: Adolescent; Anticonvulsants; Child; Epilepsy; Humans; Isoxazoles; Seizures; Zonisamide | 2007 |
Serotonin but not zonisamide inhibits theophylline-induced epileptiform activity in guinea pig hippocampal CA3 neurons.
Topics: Action Potentials; Analysis of Variance; Animals; Anticonvulsants; Dose-Response Relationship, Drug; | 2007 |
Neuroleptic malignant syndrome-like state in an epileptic patient with organic brain comorbidity treated with zonisamide and carbamazepine.
Topics: Adult; Anticonvulsants; Brain Diseases; Carbamazepine; Comorbidity; Epilepsy; Humans; Isoxazoles; Ma | 2007 |
Clinical efficacy of zonisamide in Lennox-Gastaut syndrome: Korean multicentric experience.
Topics: Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Follow-Up Studies; Humans; Infant; Isoxa | 2008 |
Antiepileptic activity of zonisamide on hippocampal CA3 neurons does not depend on carbonic anhydrase inhibition.
Topics: 4-Aminopyridine; Animals; Anticonvulsants; Carbonic Anhydrase Inhibitors; Data Interpretation, Stati | 2008 |
Nonlinear pharmacokinetics of CI-912 in adult epileptic patients.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Humans; Isoxazoles; Kinetics; Male; Middle Aged; Oxazoles; | 1984 |
Therapeutic concentration of antiepileptic drugs and the severity of epileptogenesis.
Topics: Anticonvulsants; Carbamazepine; Epilepsy; Humans; Isoxazoles; Phenytoin; Valproic Acid; Zonisamide | 1982 |
3-Sulfamoylmethyl-1,2-benzisoxazole, a new type of anticonvulsant drug. Electroencephalographic profile.
Topics: Animals; Anticonvulsants; Arousal; Cats; Electroencephalography; Epilepsy; Female; Freezing; Hippoca | 1980 |
Population analysis of the dose-dependent pharmacokinetics of zonisamide in epileptic patients.
Topics: Administration, Oral; Adolescent; Adult; Anticonvulsants; Biological Availability; Carbamazepine; Ch | 1994 |
Concentrations of zonisamide in serum, free fraction, mixed saliva and cerebrospinal fluid in epileptic children treated with monotherapy.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Drug Administration Schedule; Epilepsy; | 1993 |
Mechanisms of T-type calcium channel blockade by zonisamide.
Topics: Anticonvulsants; Calcium Channel Blockers; Cell Culture Techniques; Epilepsy; Humans; Isoxazoles; Ne | 1996 |
The necessity of adjusting the dosage of zonisamide when coadministered with other anti-epileptic drugs.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Drug Therapy, Combinatio | 1996 |
Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy.
Topics: Abnormalities, Drug-Induced; Adult; Anencephaly; Anticonvulsants; Epilepsy; Female; Humans; Infant, | 1996 |
Mechanism for reduction of serum folate by antiepileptic drugs during prolonged therapy.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Demography; Epilepsy; Fe | 1997 |
IgA and IgG2 deficiency associated with zonisamide therapy: a case report.
Topics: Anticonvulsants; Epilepsy; Humans; IgA Deficiency; IgG Deficiency; Immunoglobulin A; Immunoglobulin | 1997 |
Heat stroke-like episode in a child caused by zonisamide.
Topics: Anticonvulsants; Biopsy; Child, Preschool; Epilepsy; Fever; Heat Stroke; Humans; Hypohidrosis; Isoxa | 1997 |
Psychotic episodes during zonisamide treatment.
Topics: Adult; Age Factors; Anticonvulsants; Case-Control Studies; Child; Epilepsy; Female; Humans; Isoxazol | 2000 |
Two new drugs for epilepsy.
Topics: Adult; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Clinical Trials as Topic; Drug Inter | 2000 |
Zonisamide reduces the increase in 8-hydroxy-2'-deoxyguanosine levels formed during iron-induced epileptogenesis in the brains of rats.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Anticonvulsants; Brain Chemistry; Cerebral Cortex; Chlorides; | 2000 |
Zonisamide (Zonegran) for epilepsy.
Topics: Adult; Anticonvulsants; Ataxia; Biological Availability; Calcium Channel Blockers; Clinical Trials a | 2000 |
Effects of combined administration of zonisamide and valproic acid or phenytoin to nitric oxide production, monoamines and zonisamide concentrations in the brain of seizure-susceptible EL mice.
Topics: Animals; Anticonvulsants; Biogenic Monoamines; Brain; Disease Models, Animal; Drug Interactions; Dru | 2000 |
Alterations of nitric oxide and monoamines in the brain of the EL mouse treated with phenobarbital and zonisamide.
Topics: Animals; Anticonvulsants; Biogenic Monoamines; Brain; Disease Models, Animal; Drug Therapy, Combinat | 2001 |
Influences of caffeine to nitric oxide production and zonisamide concentration in the brain of seizure-susceptible EL mice.
Topics: Animals; Anticonvulsants; Brain; Caffeine; Central Nervous System Stimulants; Drug Interactions; Epi | 2001 |
[A case of epilepsy after therapy with interferon-alpha-treated chronic hepatitis C].
Topics: Anticonvulsants; Electroencephalography; Epilepsy; Hepatitis C, Chronic; Humans; Interferon-alpha; I | 2002 |
Pharmacokinetics of zonisamide in perinatal period.
Topics: Adult; Anticonvulsants; Chromatography, High Pressure Liquid; Epilepsy; Female; Fetal Blood; Humans; | 2002 |
Clobazam shows a different antiepileptic action profile from clonazepam and zonisamide in Ihara epileptic rats.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Circadian Rhythm; Clobazam; Clonazep | 2002 |
Methodological requirements for clinical trials in refractory epilepsies--our experience with zonisamide.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Clinical Trials as Topic; Epilepsies, Partial; | 1992 |
Factors influencing serum concentration of zonisamide in epileptic patients.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Humans; Infant; Isoxa | 1992 |
Monotherapy for childhood epilepsies with zonisamide.
Topics: Administration, Oral; Adolescent; Anticonvulsants; Child; Child, Preschool; Dose-Response Relationsh | 1991 |
Effect of zonisamide on serum immunoglobulins.
Topics: Adolescent; Adult; Anticonvulsants; Epilepsy; Female; Humans; Immunoglobulin A; Immunoglobulin G; Im | 1990 |
Effect of a novel anticonvulsant, zonisamide (AD-810, CI-912), in an experimental model of photosensitive epilepsy.
Topics: Animals; Anticonvulsants; Behavior, Animal; Cats; Dose-Response Relationship, Drug; Epilepsy; Female | 1990 |
Anticonvulsant effects of zonisamide and phenytoin on seizure activity of the feline visual cortex.
Topics: Animals; Anticonvulsants; Cats; Dose-Response Relationship, Drug; Epilepsy; Female; Isoxazoles; Kind | 1990 |
The antiepileptic effect of zonisamide on patients with refractory seizures and its side effect.
Topics: Adult; Anticonvulsants; Electroencephalography; Epilepsies, Partial; Epilepsy; Epilepsy, Absence; Ep | 1988 |
Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy.
Topics: Adolescent; Adult; Anticonvulsants; Body Weight; Carbamazepine; Drug Therapy, Combination; Epilepsy; | 1986 |